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ABSTRACT 
 
 
Human Herpesvirus 6A (HHV-6A) and 6B (HHV-6B) are ubiquitous 
betaherpesviruses. Both viruses are associated with a variety of adult disorders 
including neurological disorder, such as multiple sclerosis and chronic fatigue 
syndrome. HHV-6 viruses are capable of establishing latency by integration into the 
telomeres of the host chromosome and are transmitted in a Mendelian manner in 
approximately one percent of the population. To date little is known about the 
immunological and neurological consequences of HHV-6 inheritance. This study 
focused on a unique population of individuals that inherited HHV-6 and present with 
chronic fatigue-like symptoms, including hypersomnia, generalized fatigue, headache, 
and short term and long term memory impairment. The central hypothesis of this study 
was that active replication of HHV-6 correlates with patient symptoms. To address this 
aim we first looked at the reactivation of integrated HHV-6 in vitro by inducing viral 
replication with epigenetic modifiers trichostatin A (TSA), valproic acid, sodium butyrate, 
and carbamazepine, and found TSA to be an effective method of inducing reactivation 
of HHV-6 from its integrated form. Additionally, a reactivated HHV-6A virus isolated from 
a patient with inherited HHV-6 was fully sequenced and the nucleotide and amino acid 
sequence was compared to that of fully sequenced HHV-6 laboratory strains, as well as 
the inherited virus. The reactivated virus was found to be very similar to the HHV-6A GS 
strain; however, there was some divergence at the right end of the viral genome and 
viii 
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regions of the genome that do not contain herpesvirus core genes. Interestingly, the 
sequenced reactivated virus was found to differ from the HHV-6 virus which was 
inherited. Finally, HHV-6 replication was assessed by performing reverse transcriptase 
PCR assay for the viral glycoprotein U100 in patients receiving antiviral treatment. 
Results indicated that short term antiviral treatment was insufficient to abrogate viral 
replication, while treatment of six weeks or longer eliminated viral mRNA in patient 
blood samples. Furthermore, sequencing of the viral mRNA and inherited viral DNA 
indicate that the source of the mRNA detected in patient blood samples was an 
exogenously acquired HHV-6 virus, as the U100 glycoprotein sequences were not 
identical. Together these studies indicate that although HHV-6 can be reactivated from 
its integrated form, individuals in this unique population harbored an exogenous HHV-6 
virus, in addition to the inherited virus; we termed this condition inherited herpesvirus 
syndrome. The fact that these individuals are able to acquire exogenous HHV-6 viruses 
suggest that there may be some level of immune tolerance or immune dysfunction; we 
suggest that further studies focus on uncovering the immune response to HHV-6 in 
individuals with an inherited form of the virus. 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
 
 
Herpesviridae Structure 
The Herpesviridae family of viruses is comprised of greater than 200 
herpesviruses that infect mammals, birds, and reptiles. Irrespective of the natural host, 
all herpesvirus virions range in size from 120-260nm and have a similar structure (1). At 
the core of the virus particle, is the double stranded DNA genome that is tightly 
packaged into an icosahedral nucleocapsid comprised of 161 hexameric and 
pentameric capsomeres. Surrounding and tightly associated with the nucleocapsid is an 
amorphous, fibrous structure made of a compilation of viral and cellular proteins known 
as the tegument. Viral tegument proteins are important for propagating infection and 
often interfere with the host innate response to the virus. Examples of tegument proteins 
include HSV UL41 protein that targets cellular mRNA for degradation, and US3 that 
inhibits toll like receptor 2 (2,3). The most outer layer of the virion is a lipid bilayer 
envelope with glycoprotein protrusions. Glycoproteins often serve as ligands for cellular 
receptors or some are essential for cell fusion (1,4). 
Classification of Human Herpesviruses  
The nine human herpesviruses may be classified into three subfamilies and six 
genera based on DNA sequence, similarity of encoded proteins, site of latency, and 
other biological properties (Table 1). The human members of the Alphaherpesvirinae 
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subfamily include herpes simplex viruses 1 & 2, as well as Varicella-zoster virus; the 
Alphaherpesviruses infect and establish latency in sensory ganglia. Cytomegalovirus 
(CMV), human herpesvirus 6A, 6B, and 7, are members of the Betaherpesvirinae 
subfamily. CMV establishes latency in monocytic cells and the bone marrow; however, 
there is no conclusive evidence indicating the natural site of latency for the HHV-6 
viruses or for HHV-7. The viruses belonging to the Gammaherpesvirinae subfamily are 
known for their oncogenic potential; gammaherpesviruses establish latency in lymphoid 
cells. The two human gammaherpesviruses, Epstein-Barr virus and Kaposi’s sarcoma-
associated herpesvirus, both establish latency in B-lymphocytes.  
 
 
Figure 1: The Structure of Herpesviruses. Each herpesvirus particle is comprised of 
a double stranded DNA genome contained within a capsid, tegument, and envelope. 
Protruding from the surface of the envelope are glycoproteins (1). 
 
Genome Organization of Human Herpesviruses 
The genomes of the human herpesviruses range in size from 145 to 230 kbp (1). 
Despite some conservation in the encoded genes, the genomic arrangement varies 
from one virus to another (Figure 2). The majority of the genome length is attributed to 
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the unique length region, which contains the majority of the protein-coding genes (1). 
The unique length segment may occur as a single unit or may be separated via one or 
more blocks of intervening repeated sequences, creating a unique long or two or more 
unique short regions (1). 
 
Table 1: Classification of Human Herpesviruses (1) 
Designation  Common Name /Abbreviation Subfamily Genus 
HHV-1  Herpes simplex virus 1 (HSV-1)  Alpha  Simplexvirus  
HHV-2  Herpes simplex virus 2 (HSV-2) Alpha  Simplexvirus  
HHV-3  Varicella-zoster virus (VZV)  Alpha  Varicellovirus  
HHV-4  Epstein Barr virus (EBV) Gamma  Lymphocryptovirus 
HHV-5  Cytomegalovirus(CMV) Beta  Cytomegalovirus  
HHV-6A  Human herpesvirus 6A (HHV-6A) Beta  Roseolovirus  
HHV-6B  Human herpesvirus 6B (HHV-6B)  Beta  Roseolovirus  
HHV-7  Human herpesvirus 7 (HHV-7) Beta  Roseolovirus  
HHV-8  Kaposi’s sarcoma-associated 
herpesvirus (KSHV) 
Gamma  Rhadinovirus  
 
Additionally, the genomes of the human herpesviruses characteristically contain 
a variable number of repetitive elements at the ends and/or within the genome. When 
internal repeats are inversions of terminal or internal reiterations (inverted repeats), 
isomers may arise due to recombination of complementary sequences during viral 
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replication (1). Of the human herpesviruses, only HSV-1, HSV-2, VZV, and CMV have 
inverted repeats(1). 
The genome of HHV-6A and HHV-6B are 159kbp and 162kbp, respectively. An 
8-13kb segment, designated direct repeat left (DRL) or right (DRR)(5–7), is duplicated in 
the same orientation at both ends of the unique length. At the outer regions of the direct 
repeat are a variable number of telomere repeats that are either perfectly reiterated 
(perfect repeats) or repeated with other interspersed hexameric sequences (imperfect 
repeats) (7). The telomere repeats of HHV-6 are identical to that of the human telomere 
repeats and the perfect repeats at the right end of the viral genome are in the same 
orientation of the human telomeres, facilitating recombination between viral and host 
repeats. In addition to the telomere repeats, the genomes of HHV-6A and HHV-6B have 
major repetitive elements located at near the right end of the unique length region: R1, 
R2 , and R3; HHV-6B has an additional repetitive element R0 located at the junction of 
the DRL and the unique segment (1,5,6). 
Herpesvirus Replication: Lytic Replication, Latency, and Reactivation 
Three replication properties shared by all herpesviruses are (1) replication of the 
viral DNA within the nucleus (2) a replication cycle includes primary infection, and a 
period of lytic replication during which new virus production occurs or the establishment 
of latency, and (3) after a variable period of latency, reactivation may occur, leading to 
the production of infectious viruses.  
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Figure 2. The Genome Organization of Human Herpesviruses. Solid lines represent 
the unique length (U) regions of the genome: The unique (U), unique Long (UL), unique 
short (US), and long unique regions (LUR) are represented by solid lines. Box regions 
represent repetitive elements of the genome: TR (terminal repeats), TRL (long terminal 
repeat), or TRS (short terminal repeat). For HHV-6A, 6B, and 7 the direct repeats (DRL 
or DRR), the black boxes represent the perfect telomere repeats, while the gray boxes 
represent the imperfect telomere repeats (1,5,8,9). 
 
 Lytic Replication 
Infection of herpesviruses begins with receptor binding, fusion of the viral and 
cellular membrane, and the release of the viral genome into the nucleus of the cell (1). 
Prior to the start of lytic replication, the DNA genome of the virus circularizes, and viral 
gene products are synthesized in a lytic cascade. At the earliest time points of infection, 
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tegument proteins are expressed. Next, the immediate early (IE) genes that function as 
transcriptional regulators are expressed. IE gene expression occurs independent of 
protein synthesis, and is therefore produced in the presence of cycloheximide in vitro. 
Next, the early genes, which are expressed independently of viral DNA synthesis, are 
synthesized; these genes encode proteins such as the viral primase/helicase, and DNA 
polymerase, which are required for viral DNA replication. In the final phase of the lytic 
cascade, the late genes that encode structural proteins for new virion production, such 
as capsid proteins and glycoproteins, are synthesized.  
During DNA replication, the circularized viral genome is duplicated by a rolling-
circle mechanism (10,11). At the start of replication, a short RNA primer is made by the 
viral primase. Replication begins at an origin of replication and proceeds around the 
circle, resulting in the formation of catenated genomes. For new viral particles to be 
made, cleavage of the concatemers must occur and single length genomes need to be 
packaged into empty nucleocapsids. During lytic replication, the production and release 
of new viral particles results in the lysis of the host cell.  
Latent Infection 
As an alternate to lytic replication, herpesvirus may enter a period of latent 
infection following infection of new target cell cells (1). In contrast to lytic replication, 
gene expression is highly restricted during latency. Genes that are essential for the 
production of new viruses are repressed, and only genes required for maintenance of 
the viral genome and latency associated genes are expressed. In most cases, during 
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herpesvirus latency, multiple circularized copies of the viral genome found within the 
nucleus are tethered to the chromosome. 
Latency of HHV-6 
HHV-6A infects cells via the CD46 receptor, while HHV-6B infects cells via the 
CD134 receptor (12,13). It has been suggested that the natural site of latency for HHV-6 
viruses is the monocyte/macrophage cell population (14). Additionally, there is in vitro 
evidence of establishment of latency in other cell types including astrocytes, T-
lymphocytes (15,16). There is no conclusive evidence on the natural site of latency 
during HHV-6 infection. 
In contrast to other human herpesviruses, HHV-6 viruses do not form circular 
episomes during latency. Initial reports of HHV-6 latency in patient PBMCs indicated a 
covalent linkage between HHV-6 DNA and high molecular weight cellular DNA (17). 
However, the mechanism of latency and the orientation of the genome during latency 
were not elucidated for another decade. More recently, Arbuckle et al. demonstrated 
that latency of HHV-6 viruses occurs by homologous recombination between telomere-
like repeats at the telomeres at the end of the host chromosomes (15). This method of 
integration was observed in vitro as well as in patient PBMC samples (15). Southern 
blot hybridization and cloning and sequencing of the integration site, showed that during 
integration, the HHV-6 genome is oriented so that the perfect telomere repeats at the 
right end of the viral genome is adjacent to the subtelomere of the human chromosome 
(15). Additional experiments also demonstrate that during integration both direct repeats 
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are present and the imperfect telomere repeats at the left end of the viral genome 
adjoins the telomere of the host chromosome (18). (Figure 3) 
 
Figure 3: The Model of HHV-6 Integration. During homologous recombination the 
presence of perfect telomere repeats (black box) and imperfect telomere repeats (grey 
box) at the end of the direct repeats allow integration into the host telomeres via 
homologous recombination (18). 
 
 
Reactivation 
Herpesvirus latency is not abortive; the quiescent virus may produce infectious 
virus particles at a later point. A variety of factors may lead to the reactivation of 
herpesviruses in their natural hosts, such as immune suppression, UV exposure, and in 
some cases hypoxia (19,20). In tissue culture models, some latent herpesviruses are 
inducible by chemical compounds which serve as epigenetic modulators which alter 
chromatin structure or mediate RNA polymerase to access DNA. To name a few, DNA 
methyltransferase inhibitor, 5-azacytidine, and HDAC inhibitors, trichostatin A (TSA) and 
sodium butyrate, are all capable of inducing viral gene transcription (21–25). 
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HHV-6 History  
In 1986, HHV-6 was first isolated from the PBMCs of six immunodeficient 
individuals who presented with a variety of lymphoproliferative disorders, including 
HTLV, B-cell lymphoma, and acute lymphocytic leukemia (26). Preliminary reports 
identified the virus as a novel herpesvirus that primarily infects B-lymphocytes; 
therefore, the virus was designated human B-lymphotropic virus or HBLV (26). Shortly 
after initial identification, studies demonstrated that in culture HBLV/HHV-6 selectively 
infects and efficiently replicates in T-lymphocytes with a preference towards CD4+ T-
cells (27–29). Although HHV-6 viruses are primarily lymphotropic, additional sites of 
replication for the viruses include monocytes/macrophages, and astrocytes (14,16). 
HHV-6 Transmission 
After primary infection, HHV-6 is detectable in saliva, nasal cavity, cervix and 
female genital tract (30–32). The main route of HHV-6 transmission is oral transmission 
via saliva; most children are infected by the age of two (33). 
Additionally, HHV-6 viruses may be transmitted congenitally by one of two 
mechanisms: transplacental/perinatal infection or inheritance (15,34–38). Integration of 
HHV-6 in the telomeres of germline cells, a condition known as chromosomally 
integrated HHV-6 (CIHHV-6), results in vertical transmission of the virus in a Mendelian 
manner. All CIHHV-6 positive individuals harbor one copy of the viral genome in every 
nucleated cell; there has been a single report of an individual who inherited one copy of 
the viral genome from each parent (37). Over the past twenty years, several 
independent groups reported HHV-6 integration/inheritance; evidence was primarily 
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obtained by fluorescent in situ hybridization studies to determine integration site (38–
41). More recently, Arbuckle et al. cloned and sequenced the integration site, while also 
performing partial sequence analysis to confirm that the integrated virus is the same in 
all CIHHV-6 family members (15). The rate of inheritance in the general population is 
approximately 1% in the United States and the United Kingdom, with an increased 
prevalence seen in hospitalized patients (40,42–49). To date eight unique HHV-6 sites 
of integration have been reported in the literature: 1q, 9q, 10q, 11p, 17p, 18q, 19q, 22q 
(15,17,37–39,50–53). Congenital HHV-6 infection may also result from intrauterine or 
transplacental infection. HHV-6 has successfully been detected in cervical swabs of 
pregnant women (30,54), as well as in placenta samples obtain during birth (55), and 
recent reports confirm that transplacentally acquired HHV-6 may occur due to 
reactivation of a maternal chromosomally integrated HHV-6 (CIHHV-6) strain (30,36). 
Although inheritance of HHV-6 is relatively low in the general healthy population, it is 
considered the major mode of congenital infection (34). 
Transplant related HHV-6 transmission may also occur by either donor 
transmission or reactivation of the virus. Transmission of integrated HHV-6 via 
transplant has been noted in hematopoietic stem cell recipients, as well as liver, kidney, 
and small bowel transplant patients (40,45,46,56). The implications of CIHHV-6 
transmission is not fully understood; however, a common problem is misdiagnosis of 
active replication and treatment with antivirals in the absence of HHV-6 related clinical 
symptoms (41,51,57,58). Additionally, transmission via solid organ transplantation 
resulting in antibody responses characteristic of primary HHV-6 infection has been 
documented (59). 
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HHV-6 Epidemiology 
Prevalence 
Seroprevalence of HHV-6 ranges up to 100% in most regions of the world (60). 
However, there is a disproportionate number of childhood infections with HHV-6B in the 
United States, Japan, and some regions of Europe, rather than HHV-6A (61,62). In 
these regions, infections with HHV-6A are generally seen in adult populations who are 
experiencing immunological or neurological disorders. An exception to this trend is seen 
in regions of Sub-Saharan Africa, where the prevalence of HHV-6A is as high as 85% in 
healthy children (63).  
The rate of inheritance of HHV-6 is approximately 1% in the United States and 
the United Kingdom. However, and increased prevalence has been noted in some 
populations of transplant patients and pediatric encephalitis patients (34,42,46,56,64–
67). Inheritance of both HHV-6A and HHV-6B occurs. However, there are insufficient 
data at this time to determine which variant is most commonly inherited. 
HHV-6 Disease Associations and Complications  
Exanthema subitum 
In most regions of the world, primary HHV-6B infection occurs by the age of two 
and the virus is considered ubiquitous in the healthy population (1,68). HHV-6B is one 
of the causes of exanthema subitum, also known as roseola infantum or sixth disease 
(69). Exanthema subitum is characterized by a sudden onset fever, followed by a rash 
on the trunk, extremities, and face. Although rare, complications associated with 
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exanthema subitum include convulsions and encephalitis (1). Primary infection with 
HHV-6 in adults is rare, but may result in a mononucleosis-like disease (70). 
AIDS Progression 
While HHV-6A has not conclusively been implicated as the etiological agent for 
any diseases, it may play a role in AIDS progression. HHV-6 viruses predominantly 
replicate in CD4+ T-cells, the target cells of the HIV virus. In vitro, HIV and HHV-6 can 
together productively infect CD4+ T cells, and dual infection has been noted in infants 
and adult (62,63). HHV-6 infection leads to trans-activation of HIV LTR and increased 
HIV gene expression  (71,72). Furthermore, in a pig-tail macaque model, animals 
infected with both HHV-6A and simian immunodeficiency virus (SIV) progression to 
AIDS and depletion of CD4+ and CD8+ cells occurred faster than in animals infected 
SIV alone.(73). Accelerated progression to AIDS was also noted when animals were 
infected with HHV-6 prior to SIV infection. 
Multiple Sclerosis 
The cellular receptor for HHV-6A viruses is the ubiquitously expressed CD46 
receptor; in contrast, CD134 is used by HHV-6B viruses for infection. In vitro studies 
have demonstrated experimental infection of a variety of cell types including neuronal 
cells (12,16,74) with both viruses. The nasal cavity is a reservoir for HHV-6 viruses; and 
from there HHV-6 gains access to the central nervous system via the olfactory pathway 
(31). Both HHV-6A and HHV-6B are able to infect cells of neuronal origin. However, 
only HHV-6A is able to establish productive infection in astrocytes and 
oligodendrocytes; HHV-6B infection in these cell types is abortive (16,31,74,75). 
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It has been suggested that HHV-6 plays a role in the progression of multiple 
sclerosis (MS); however, this relationship remains controversial. Staining of neurons 
and oligodendrocytes on brain specimens in the United States detected using 
antibodies against HHV-6 virion protein and DNA binding protein in both control and MS 
brains. However, HHV-6 antigen detection in oligodendrocyte and neuronal plaques 
was significantly higher in MS brains than control brains (76). Other studies describe 
significance higher prevalence of IgG titers directed at the HHV-6 U94 rep homologue 
protein and elevated IgM antibody directed against p41/38 HHV-6 early antigen in MS 
patients during relapse (77–79). HHV-6 DNA and infectious virus could also be detected 
and isolated from the cerebral spinal fluid of MS patients (79,80). Despite these data, 
contradicting reports have found no significant differences in DNA and antibody levels 
between individuals with MS and controls (81).  
Chronic Fatigue Syndrome 
Chronic fatigue syndrome (CFS) is a chronic multi-systemic disease 
characterized by long-standing fatigue, impaired memory and concentration, 
hypersomnia, headache, and musculoskeletal pain (82). Additionally, individuals 
suffering from CFS also present with hypothalamic dysfunction and quantitative 
encephalography consistent with encephalopathy (83,84). To date, the etiological agent 
of CFS has not been established. However, many have suggested that a viral agent 
may be a trigger because patients often report having flu-like symptoms prior to CFS 
onset (84,85).  
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HHV-6 exhibits immunomodulatory effects and has the ability to productively 
infect cells of neuronal origin; thus, many have suggested these viruses to be a trigger 
for CFS (84). In the literature, there are reports supporting and refuting these claims. 
Studies supporting a role for HHV-6 in CFS, indicate a significant increase in antibody 
titers to HHV-6 early antigen p41 and late antigen gp110 in affected individuals (86). 
Elevated titers suggest viral reactivation; improved cognitive function was also 
described with the use of valganciclovir treatment in individuals with elevated HHV-6 
titers (83,87). However, other studies found no difference in HHV-6 IgG levels in 
individuals with CFS (88) 
Research on the role of HHV-6 in CFS pathology is far from complete. For 
example, the prevalence of CIHHV-6 in the CFS population has not been fully explored. 
CIHHV-6 adds a level of complexity to the question of how HHV-6 affects CFS 
pathology because inheritance of the virus may potentially alter an individual’s immune 
response and may contribute to the disease pathology. 
Drug-Induced Hypersensitivity 
Drug-induced hypersensitivity (DIHS)/drug rash with eosinophilia and systemic 
symptoms (DRESS) is a rare but severe systemic drug allergic reaction, characterized 
by rashes, fever, and lymphadenopathy. Triggers for DIHS/DRESS include 
anticonvulsants, some classes of antibiotics, and anti-inflammatory drugs (50,89,90). 
Many anticonvulsants, such as valproic acid and carbamazepine, are HDAC inhibitors; 
thus, these epigenetic modifiers often lead to the reactivation of latent herpesviruses. 
Multiple studies have linked HHV-6 to DIHS; HHV-6 replication has been detected in 
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DIHS skin lesions and anti-HHV-6 IgG and IgM has also been detected in patient 
serum. The presence of both HHV-6 specific IgM and IgG during DIHS, suggests that 
primary HHV-6 infection and HHV-6 reactivation may be contributing factors to the 
syndrome. 
HHV-6 Detection in Clinical Samples 
The most common method for detecting primary HHV-6 infection is indirect 
immunofluorescence to detect anti-HHV-6 IgM and IgG antibodies (91,92). Additionally, 
active replication may be detected by PCR or RT-PCR for the detection of viral DNA or 
RNA in plasma or serum or whole blood (92–95). Following primary infection, IgG 
antibodies often persist and IgM antibody diminish and do not always reappear with 
reactivation. Therefore, quantitative PCR is most often used for detecting viral 
reactivation or reinfection. Different methodologies, however, must be used to detect 
active HHV-6 replication in individuals with CIHHV-6. 
In contrast to transient infections with HHV-6, CIHHV-6 positive individuals 
exhibit a persistent high viral load (1x 106-1 x 107 copies/ml) in PBMCS, and hair 
follicles, leukocytes, and other clinical samples are also positive (34,96,97). The 
antibody response to HHV-6 in CIHHV-6 harboring individuals is variable with regards to 
the presence of IgG antibodies in the serum of these individuals (37,38). In vitro studies 
and clinical reports indicate that HHV-6 may be reactivated from its integrated form 
(15,36); however detection of reactivation in samples from individuals with CIHHV-6 is 
difficult using PCR based methodologies. HHV-6 antibody response during reactivation 
is also variable and may yield inconclusive results. Detection of mRNA, however, seems 
15 
 
to be a promising marker for viral reactivation; thus, several research groups 
successfully detected active HHV-6 replication using reverse-transcriptase PCR based 
assays (30,35,93–95,98).  
Conserved and Unique Genes of HHV-6 
The genomes of HHV-6A and HHV-6B are colinear to human cytomegalovirus 
and to date there are greater than sixty open reading frames with known or implied 
function (99). Protein-encoding open reading frames occur within the unique length 
region as well as the direct repeats of the virus, and proteins are encoded on both 
strands of the viral genome. Similar to other herpesviruses, the majority of genes 
encoded by HHV-6A and HHV-6B are conserved across all herpesvirus subfamilies. 
Conserved herpesvirus genes include tegument and capsid proteins, and proteins 
essential for the helicase/primase and DNA polymerase complex. Additionally, one 
block of genes at the left end of the virus (U2 to U19) is specific to betaherpesviruses; 
and another seven other genes are unique to roseoloviruses (U20, U21, U23, U24, 
U24A, U26, U100). There are only five genes that are unique to HHV-6A/6B.  (Table 2) 
HHV-6 Interstrain and Intrastrain Variation 
To date, four HHV-6 genomes have been completely sequenced (Table 3) 
(5,6,9,100). Whole genome sequence comparison has been performed comparing the 
two B viruses, HST and Z29, to HHV-6A U1102 (5,6). The sequencing for HHA-6A GS 
has been completed and made available recently; however, the genetic relationships 
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 Figure 4: A Diagram of the HHV-6 Genome. The HHV-6 genome includes 7 gene 
blocks with are conserved across all herpesvirus subfamilies (numbered open arrows), 
as well as one gene block specific to betaherpesviruses.  The black boxes indicate the 
perfect telomere repeats, while the gray box represents the imperfect telomere repeats. 
(5,99) 
 
Table 2: HHV-6 Specific Genes  
Gene ID Gene Product 
DR3 MicroRNA  
U6 Unknown 
U22 Glycoprotein 
U83 Chemokine/Cytokine 
U94 Parvovirus rep homologue 
 
between the GS and other sequenced HHV-6A viruses have yet to be been elucidated. 
Full genome studies focusing on intrastrain variation are also limited. However, studies 
have looked at the nucleotide and amino acid sequence variation of several genes in 
clinical samples, and there are preliminary data on partial differences between HHV-6B 
Z29 and HHV-6B HST (5,6). 
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The amino acid identity between HHV-6A and B isolates averages approximately 
90% (5,6). The center of the genome (U32-U77) is highly conserved, and the most 
conserved open reading frames include the genes encoding the helicase/primase 
complex (U77), capsid assembly proteins (U40), and the putative terminase (U60/66). 
The region of greatest divergence is the right end of the genome, which encodes open 
reading frames U86 to U100 as well as the three major repetitive elements, R1, R2, and 
R3. The amino acid identity in this region is 72% (5). Other variable genes, such as U47 
(glycoprotein) and the U83 (chemokine) are scattered throughout the genome and are 
generally located between conserved herpesvirus gene blocks (Figure 4). In addition to 
differences in protein encoding genes, HHV-6B viruses have an expanded DR region, 
when compared to HHV-6A U1102 (5,6). 
A few studies have focused on the nucleotide and amino acid sequence 
divergence in clinical samples. Sequence analysis from clinical strains isolated from the 
United States, Japan, Germany, Uganda and Zaire highlights key differences 
demonstrating inter and intrastrain variation (101). For the U38 chemokine, the amino 
acid identity between HHV-6A U1102 and HHV-6BZ29 is 85.7% (5). Key interstrain 
differences are as follows: (1) none of the HHV-6A viruses encode a mature chemokine 
with a functional signal peptide (2); the majority ofU83A isolates have a 2 amino acid 
truncation at the C-terminus., with U1102 being the exception (101). Upon further study, 
HHV-6B viruses could further be divided into groups, one group with a shortened signal 
peptide and the other group, which includes HHV-6BHST and HHV-6BZ29 with a full 
length signal peptide. Intrastrain amino acid divergence for the B isolates ranged from 0 
to 3.5% (101). 
Glycoproteins B and H are highly conserved in the herpesvirus family; however, 
distinct differences in nucleotide and amino acid sequences between variants clearly 
segregate HHV-6A viruses from HHV-6B. Intrastrain variation in the amino acid 
sequences of 31 HHV-6B clinical samples was 0.9% and 0.3% for gB and gH, 
respectively (102). Despite the small magnitude of difference within strains, the B 
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isolates could be further segregated into two groups based on gB and gH sequences. 
The segregation, however, differed depending on which gene was analyzed, suggesting 
that intrastrain recombination between HHV-6B viruses may occur (102). 
Other studies on inter and intrastrain variation in clinical samples focused on 
envelope glycoprotein O (U47), and the polymerase processivity factor (U27). 
Sequencing of the hypervariable gene U47 gene is useful for genotyping HHV-6 viruses 
in clinical samples (63,103). Amino acid sequence identity between U1102 and GS is 
97.5%, while the identity to HHV-6B Z29 is only 89%. Sequencing results of a portion of 
the U47 reports up to 6% variation within HHV-6 variants for this region and up to 8% 
variation between groups (103). In other studies by Bonnafous et al., the interstrain 
variation for the U27 DNA polymerase processivity factor gene is 7.6% when comparing 
HHV-6A and HHV-6B clinical isolates, while intrastrain differences were 1.2% and 0.3%, 
for A and B isolates, respectively (104).  
 
Table 3: Fully Sequenced HHV-6 Strains  
Strain Genbank Accession  Geographic Location 
of Isolation 
HHV-6A U1102 NC_001664 Uganda 
HHV-6A GS KC465951 North America 
HHV-6B Z29 NC_000898 Zambia 
HHV-6B HST AB021506 Japan 
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Adaptive Immune Response to HHV-6 Infection 
Cellular Response to HHV-6 
Both CD4+ and CD8+ HHV-6 specific T-cells have been isolated from the 
PBMCs of healthy donors. In the case of both CD4+ and CD8+ the frequency of HHV-6 
specific T-cells is low, but the responding population could be expanded in vitro (105–
107). Expanded CD4+ and CD8+ populations characteristically secrete IFNγ and TNFα, 
while also performing cytolytic functions mediated by the secretion of perforin (CD4+) or 
granzyme B (CD8+) (105,106,108). Additionally, CD8+ clones were found to also 
secrete granulocyte macrophage stimulating factor. Studies on T-cell response to HHV-
6 have identified 8 HLA-DR restricted CD4+epitopes and 5 HLA-A restricted CD8+ 
epitopes (105–107).  
 
Table 4: HHV-6 T-cell Epitope Specificity (105–107) 
  CD4+ CD8+ 
Gene ID Gene Product   
U11 Tegument/Antigenic virion protein + + 
U14 Phosphorprotein 85 + + 
U38 DNA Polymerase +  
U48 Glycoprotein H +  
U54 Virion transactivator + + 
U57 Capsid Protein +  
U71 Myristolated virion protein + + 
U90 Immediate early transactivator + + 
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Antibody Response to HHV-6 
During primary infection, anti-IgG and anti-IgM antibodies are produced, with IgM 
antibodies being the first to be detected (67,91). IgG titer begins to increase about one 
week post infection and peaks a week later. Additionally, there is an increase in IgG 
avidity over the course of infection (60,67). 
The antibody response to HHV-6 in CIHHV-6 harboring individuals has not been 
clearly defined; thus, studies in the future should focus on this topic. However, one 
study by Tanaka-Taya et al. measured antibody titer to two HHV-6 antigens (IE-A and 
glycoprotein gB) in the PBMCs of CIHHV-6 individuals and compared the response to 
that of healthy non-CIHHV-6 individuals (38). Interestingly, 57% of individuals with 
CIHHV-6 had antibodies to the IE-A antigen present in the serum, while IE-A antibodies 
were undetectable in non-CIHHV-6 individuals. On the other hand, 14% of CIHHV-6 
versus 60% of the healthy individuals had an antibody response to gB (38). 
Glycoprotein B is considered one of the major neutralizing epitopes and variant specific 
gB antibodies have been detected (109). The absence of gB antibodies or reduced anti-
gB titers may reduce the ability of CIHHV-6 individuals to mount an immune response to 
an exogenous HHV6 infection. 
Treatment of HHV-6 Associated Diseases 
Primary HHV-6 infections are usually self-limiting and do not require antiviral 
therapy. However, in the case of complications due to viral reactivation antiviral 
treatment may be necessary until symptoms subside. HHV-6 viruses do not respond to 
the nucleoside inhibitors acyclovir and pencyclovir, in vitro or in vivo (110). Patients 
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experiencing HHV-6 related post-transplant complications, such as encephalitis, 
respond best to valganciclovir and foscarnet, or the pyrophosphate analogue, cidofovir 
(53,110,111). Additionally, a preliminary study by Montoya et al. recently described the 
successful treatment with valganciclovir of two related patients with chromosomally 
inherited HHV-6 who were exhibiting neurological symptoms in conjunction with active 
HHV-6 replication (83). However, to date no drugs have been approved by the FDA 
specifically for the treatment of HHV-6. 
Coinfection and Superinfection with Herpesviruses 
Reinfection with HHV-6 has been noted, suggesting that despite the 
development of neutralizing antibodies and T-cell immune responses the virus is able to 
subvert the immune system. Indirect evidence supporting the possibility of co-infection 
and superinfection in children comes from a study by Bates et al (63). In this study, 
febrile and non-febrile children in Zambia were tested for HHV-6 prevalence and the 
detected viruses were genotyped by determining the amino acid sequence of the U47 
envelope glycoprotein O. In this study, co-infections were reported at a rate of 21% to 
50%, in non-febrile and febrile children, respectively. Thirteen percent of the non-febrile 
children had co-infection with both HHV-6A and HHV-6B at 18 months of age; co-
infection with both variants was associated with an elevated viral DNA load in the serum 
of nearly four times the average for a single infection. HHV-6 reinfection was also noted 
in a study of children in the United States (112). More recently, Burbelo et al. designed 
a novel HHV-6 variant specific serological test for the detection of HHV-6A and HHV- 
6B U11 antigen (88). In a screening of 25 African serum samples, 50% of the samples 
HHV-6A seropositive and 80% were HHV-6B seropositive. This implies that a fraction of 
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the individuals in this study had either been reinfected by another HHV-6 virus or 
superinfected with both HHV-6 variants prior to seroconversion. The information on 
reinfection and superinfection in CIHHV-6 positive individuals is limited; thus, no reports 
of this nature have been reported prior to the current study. 
Human cytomegalovirus, another betaherpesvirus, is associated with 
encephalitis, retinitis, and other diseases in the immunocompromised. In individuals with 
a functional immune system, CMV establishes persistent infection in salivary gland 
tissue and myeloid cells and viral shedding may occur for years after primary infection 
(113). Despite robust antibody production in response to CMV and the high frequency of 
CMV-specific T-cells in the peripheral blood, asymptomatic CMV reactivation is frequent 
in healthy individuals and constant immune surveillance is needed to control the virus 
(114–116). Additionally, mixed infections frequently occur and individuals with persistent 
infection may be superinfected with additional strains of the virus (117). The key to CMV 
persistent infection and superinfection is the subversion of the host immune system by 
viral proteins which inhibit MHC function (118). Furthermore, a functional consequence 
of persistent CMV infection is immunosenescence: excessive expansion of CMV-
specific T-cell clones lead to premature senescence and reduced T-cell responsiveness 
(119).  
Development of Immune Tolerance 
During development, multiple mechanisms are used to ensure self-tolerance. In 
the thymus, T-cells that are specific to self-antigens are deleted by negative selection 
(120). In the periphery, presentation of self-antigens in the absence of co-stimulatory 
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molecules leads to T-cell anergy or inactivation (121). For B-cells, self-tolerance occurs 
by one of three mechanisms: receptor editing to replace self-reactive receptors, deletion 
of self-reactive clones, and anergy (122). 
Inheritance of HHV-6 presents the possibility for immune tolerance to viral 
antigens. CIHHV-6 reactive T-cells may be deleted by negative selection during 
development or T-cell anergy may be induced. Humoral responses may also be lower, if 
viral genes are expressed during development and are recognized as self. Alternately, 
in the event that reactivation of the inherited virus occurs after birth and CIHHV-6 
specific antibodies or T-cells are developed. These individuals may still be susceptible 
to superinfection if the exogenous virus differs significantly from the inherited virus. 
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OBJECTIVES AND HYPOTHESIS OF THE CURRENT STUDY  
 
 
This study focuses on a unique patient population that displays chronic fatigue 
syndrome-like symptoms, such as CNS dysfunction (impaired concentration and short 
term memory, and mild dementia), headache musculoskeletal pain, headache, and 
long-standing fatigue and has inherited HHV-6. The central hypothesis of this study 
is that these CIHHV-6 harboring patients suffer from CFS-like symptoms because 
of reactivation/active replication of HHV-6. Investigation of this hypothesis will be 
accomplished by three specific aims.  
1: Test the ability of various compounds to cause reactivation of CIHHV-6 in vitro. 
The rationale for this is aim was that quantitative PCR is unable to differentiate between 
actively replicating HHV-6 virus in patients with CIHHV-6; therefore, it is essential to 
develop an assay to detect replicating virus.  
2: Test in vivo reactivation of latent HHV-6 in patient samples. In this part 
epigenetic modifiers will be used to induce replication of latent HHV-6 in patient 
samples, and the induced virus will be characterized and compared to prototype HHV-6 
strains and to the inherited virus.  
3: Test the efficacy of antiviral treatment in suppression of HHV-6 
reactivation/replication in patients with CFS-like symptoms. The purpose of the final aim 
is to correlate HHV-6 replication status with neurological symptoms and evaluate the 
25 
 
effect of short term and long term antiviral treatment. Additionally, the prevalence of 
CIHHV-6 will be assessed in a population of individuals displaying CFS-like symptoms.  
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MATERIALS & METHODS 
 
 
Note to Reader 
Portions of this chapter have been previously published in Journal of Medical 
Virology, 2013, 85(11): 1940-1946 and has been reproduced with permission from 
Wiley Periodicals, Inc. 
Study Subjects, Treatment, Statistical Analysis 
Four patients diagnosed with inherited HHV-6 provided written informed consent 
prior to the start of this study, and the study was approved by the Institutional Review 
Board. All subjects presented with more than 0.5 million DNA copy numbers of HHV-6 
in whole blood, with concomitant positive results of HHV-6 in hair follicles as detected 
by Viracor-IBT laboratories, Inc. Patients presented with fatigue and neurological 
symptoms including, but not limited to, depression, hypersomnia, memory and cognitive 
impairment. In this study, patients received therapeutic antiviral therapy consisting of 
either twice daily valganciclovir (patients 1, 2, and 3) or 60 mg/kg foscarnet (patient 4) 
per day. Patients receiving short term treatment received 900 mg valganciclovir twice 
daily; patients receiving long term treatment received 900mg valganciclovir twice daily 
for three weeks and 450mg twice daily for three weeks or longer. Blood samples were 
collected in Quiagen PAXgene DNA, RNA, and heparin tubes before and during 
treatment.  
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A two-tailed Fisher exact test was used to determine the significance of CIHHV-6 
prevalence among a cohort of 337 US adult patients suffering from neurological 
symptoms. 
Isolation of RNA & DNA from Blood or PBMCs 
For RNA isolation, patient whole blood was collected in Quiagen PAXgene blood 
RNA tubes and incubated at room temperature for at least 2 hours prior to processing. 
Cells from whole blood were pelleted by centrifugation for 10 minutes at 3,780 rpm 
(3,000xg) in a Fisher Scientific accuSpin 1R (rotor #3450). Alternately, PBMCs or 
immortalized T-cells were pelleted at 1,500 rpm in a Fisher Scientific accuSpin 1R (rotor 
#3450). After collection by centrifugation, cells were homogenized with TRIzol Reagent 
(Invitrogen), separated with chloroform, precipitated with isopropanol, and washed with 
75% isopropanol. The pelleted RNA was resuspended in diethyl pyrocarbonate (DEPC)-
treated water.  
For DNA isolation, patient whole blood was collected in Paxgene blood DNA 
tubes, and DNA was isolated using Wizard Genomic DNA Purification Kit (Promega). 
Alternately, for DNA isolation from cells, cells were pelleted at 1,500 rpm in a Fisher 
Scientific accuSpin 1R (rotor #3450) and DNA isolation was also performed using 
Wizard Genomic DNA Purification Kit (Promega), according to the manufacturers 
protocol. 
Isolation of DNA from Agarose Gel and Cloning  
Amplified PCR products were separated on a TBE agarose gel and visualized 
using ultraviolet light. Bands corresponding to the PCR-amplified products were excised 
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and DNA was isolated from the gel fraction using the Wizard SV Gel and PCR Clean-Up 
System (Promega). The DNA was then TA cloned using the PCR4 TOPO (Invitrogen) or 
pGEMT-Easy (Promega) cloning system. For DNA generated using the Primestar High 
Fidelity Polymerase, an A-tailing reaction was performed prior to TA cloning. Briefly, the 
purified PCR fragment was incubated with 0.2mM dATP and 5 units of RedTaq 
Polymerase (Sigma) for 30 minutes at 70 ºC. The A-tailed product was then ligated with 
the TA vector  
For PCR4 TOPO cloning system, 1.5µl of the ligated DNA was mixed with 50µl of 
competent E. coli ElectroMAXDH10B strain (Invitrogen) and incubated on ice for 30 
minutes. The chilled DNA/bacteria mixture was then put into a 1mm gap cuvette and 
electroporated at 1500V. The transformation mixture was then incubated in SOC broth 
for 1 hr at 37º C with rotation, and the incubated mixture was plated on Luria Burtani 
(LB) plates containing 50 mg/ml kanamycin and 40mg/ml X-gal (5-bromo-4-chloro-3-
inodyl-β-D-galactopyranoside). The composition of LB plates is as follows: 10g tryptone 
and sodium chloride, 5g yeast extract per 1 liter of water, pH 7.5). The plates were 
incubated for 14-16 hours at 37 C.  
For the pGEMT-Easy cloning system, 2µl of ligated DNA was mixed with 40µl of 
competent JM109 (Promega) and incubated on ice for 20 minutes. The DNA/bacteria 
mixture was then incubated at 42ºC for 45 to 50 seconds. The transformation mixture 
was then incubated in SOC broth for 1.5 hr at 37º C with rotation. The incubated mixture 
was plated on LB plates containing 100 mg/ml ampicillin with 80µg/ml X-gal and 0.5mM 
IPTG (Isopropyl-β-D-thiogalactopyranoside). The plates were then incubated for 14-16 
hours at 37º C.  
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The following day, white colonies were picked and incubated in 4 ml of LB 
containing 50mg/ml kanamycin or 100mg/ml ampicillin and incubated with shaking for 
16 hours. Three milliliters of liquid cultures were used for plasmid isolation using the 
Fermentas Gene Jet Plasmid Miniprep Kit. Restriction enzyme digestions with EcoRV 
were performed on isolated plasmids to confirm the presence of the correct sized 
inserts.  
HEK293 Single Cell Clones & Fluorescent In Situ Hybridization 
HEK293 cells were infected with HHV-6A U1102, and single cell clones were 
obtained by limited dilution and seeding in a 96 well plate. Individual clones were 
expanded and maintained in DMEM (Dulbecco’s Modified Eagles Medium) with 10% 
FBS (Fetal Bovine Serum), supplemented with 50µg/ml gentamicin. Genomic DNA was 
isolated from each clone using the Wizard Genomic DNA purification kit. To confirm 
HHV-6 infection, PCR assay was performed to detect HHV-6 ORF U94 and subsequent 
agarose gel electrophoresis.   
To confirm integration of the HHV-6A genome, single cell HEK293 cells were 
treated with colcemid and harvested according to standard cytogenetic protocol (123). 
Metaphase chromosomes were by hybridized with fluorescein labeled HHV-6A U1102 
cosmid probes pMF335-631 and pMF311-12 (124). Five or more metaphase 
chromosomes were examined for each cell line. FISH experiments were performed at 
the University of Minnesota Cytogenetics Core Laboratory.  
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In vitro Reactivation of Integrated HHV-6 and Virion DNA Isolation: Patient 
Samples 
Patient PBMCs were isolated by density gradient centrifugation (Lymphoprep) 
and maintained in RPMI-1640 medium with 10% FBS and 50µg/ml gentamicin and 
treated with 10 ng/ml TPA (12-O-tetradecanoylphorbol-13-acetate) and 10ng 
hydrocortisone as previously described (15). Patient cells were co-cultured with Molt3 T-
cell line for two weeks until the formation of syncytia was observed. Virion particles were 
isolated by centrifugation of supernatant from infected cells at 27,000rpm in a Beckman 
L7-65 ultracentrifuge (SW41 rotor). Following centrifugation, DNA was extracted using 
Wizard Genomic DNA Purification Kit (Promega) or phenol chloroform extraction. 
Reactivation of Integrated HHV-6: HEK293 Clones and Assay to Detect Catenated 
Genomes 
HEK293 cell clones harboring integrated HHV-6A were maintained in DMEM with 
10% FBS and with 50µg/ml gentamicin and treated varying concentrations (160 ng/ml, 
80 ng/ml, 40 ng/ml, 20 ng/ml or 10 ng/ml) of TSA for three days. Alternately, single cells 
were treated with the same concentrations of sodium butyrate, carbamazepine, or 
valproic acid. Untreated cells were used as a negative control in all experiments. 
After treatment, DNA was isolated from the cells using Promega’s Wizard 
Genomic isolation, and PCR amplification was performed to detect catenated genomes 
(Figure 5). Amplified DNA was separated by agarose gel electrophoresis, blotted onto 
nitrocellulose, and probed with α32-dATP DR probes or with α32-dATP HHV-6A BAC 
vector probe. 
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 Figure 5: Schematic of PCR Assay for Detecting Catenated Viral Genomes. After 
induction with various epigenetic modifiers, PCR will be performed with primers specific 
to the unique length of the HHV-6 viral genome. A PCR product will only be generated if 
the viral genome is joined in a head –to-tail manner.  
 
cDNA Synthesis and Nested Reverse Transcriptase PCR Assay 
Blood samples were collected in PAXgene blood RNA tubes and RNA was 
isolated using Trizol reagent. Briefly, 30 ng of total RNA and random primers were used 
for first strand cDNA synthesis using the GoScript Reverse Transcription System 
(Promega). Alternately, RNA isolated from uninfected or infected Molt3 T lymphocytes 
was used as a negative or positive control, respectively. An equivalent of 5ng of total 
RNA was used for nested PCR reaction. 
Two rounds of PCR were performed to using RedTaq Polymerase (Sigma) and 
primers specific to the U100 glycoprotein. For a cellular control, beta actin was amplified 
with 30 cycles of PCR. Additionally, a reverse transcriptase null reaction was performed 
to ensure the absence of DNA in RNA samples. Amplified products were separated by 
agarose gel electrophoresis, stained with ethidium bromide, and visualized using 
ultraviolet light in the Gel Doc Molecular Imaging System (Bio-Rad). 
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Table 5: Primers Used for Nested RT-PCR and Beta Actin 
 Primer Name Sequence 
U100 Outside F (93)] 5’-CTAAATTTTCTACCTCCGAAATGT-3’ 
U100 Outside R (93) 5’-GAGTCCATGAGTTAGAAGATT-3’ 
U100 Inside F (93) 5’-ACTACTACCTTAGAAGATATAG-3’ 
U100 Inside R (93) 5’-AAGCGCGTGCAGGTTTCCCAA-3’ 
Beta actin F  5’-CTGGAACGGTGAAGGTGACA-3’ 
Beta actin R  5’-AAGGGACTTCCTGTAACAATGCA-3’ 
 
 
Table 6: PCR Cycling Conditions: U100 Nested RT-PCR 
Step Temperature (ºC) Time (minutes) Number of 
cycles 
Initial denaturation  94 2  1x 
Denaturation 94 1  30x 
Annealing 43 (outside)/53 
(inside) 
2  
Extension 72 1.5  
Final Extension 72 5 1x 
 
Table 7: PCR Cycling Conditions: Beta Actin 
Step Temperature 
(Celsius) 
Time (minutes) Number of 
cycles 
Initial denaturation  94 2  1x 
Denaturation 94 1  30x 
Annealing 52 2  
Extension 72 0.5  
Final Extension 72 5 1x 
 
PCR Amplification for Sequence Comparison or Detection of Viral DNA in Infected 
Cells 
Selected HHV-6 open reading frames were amplified by PCR amplification using 
DNA isolated from whole blood or PBMCs as a template. Primestar High Fidelity 
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Polymerase (Takara) was used to perform each reaction. Two step or three step 
amplification was performed, according to the manufacturer’s protocol. To confirm viral 
infection, ORF U94 was amplified by PCR with RedTaq polymerase and using DNA 
isolated from HHV-6A infected HEK293 single cell clones as a template. 
Sequencing 
For cDNA sequencing and sequencing for genome comparison clones were 
sequenced at the Moffitt Cancer Center Molecular Genomics Core Facility using the 
ABI3130XL capillary sequencing instrument. Alternatively, pyrosequencing of virion 
DNA was performed at the Recombinant Herpesvirus and HTS sequencing Core 
Laboratory at the University of Florida using the Roche 454 GS-FLX Assembly of the 
consensus sequence obtained from pyrosequencing was assembled using HHV-6A 
U1102 as a reference. 
Restriction Digest and Southern Blot for Comparison of Inherited and Reactivated 
Viral Genomes  
For evaluating the heterogeneity in inherited HHV-6 strains, 5 µg of cellular DNA 
from patient PBMCs or 1ng of virion DNA was digested with SacI. For comparison of the 
reactivated HHV-6 strain to the U1102 prototype strain, 45 ng of virion DNA was 
digested with BamHI and SacI. Digested DNA was separated agarose gel run in 1x TBE 
buffer, stained with Sybr Green (Manufacturer) or ethidium bromide and visualized 
using the GE Typhoon Imager or Bio-Rad Geldock, respectively. 
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Southern Blot 
Preparation of Gel for Transfer 
After separation of DNA on an agarose gel run in 1xTBE Buffer, the gel was 
incubated under the following conditions with gentle rocking to prepare the gel for DNA 
transfer. 
Table 8: Southern Blot Gel Preparation  
Step Solution Incubation time 
(minutes) 
Number of 
washes 
Depurination 0.25M HCl 10 2 
DNA 
denaturation 
1M NaCl, 0.5M 
NaOH 
15 2 
Neutralization 1.5M NaCl, 0.5M 
TrisHCl 
15 2 
 
Transfer 
After washing was completed, the gel was transferred to Hybond C mixed ester 
nitrocellulose by vacuum blotting for 30 minutes (125). A 10x saline sodium citrate 
(SSC) solution was used as a transfer agent to prevent gel from drying during transfer. 
After transfer, the DNA was immobilized by baking the membrane at 80ºC for one hour.   
Preparation of α32-dATP Probe 
An HHV-6A BAC vector was used to generate an α32P-dATP probe (4).  Initially, 
a combination of 20-100ng BAC vector DNA, 1.5µg random primers (Promega) was 
heated at 100 ºC for 3 minutes. Following denaturation, 50 µM dNTP-dATP, 5U DNA 
Polymerase I Klenow, DNA polymerase buffer (to a final concentration of 1x), and 50 
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µCi α32-P dATP (Perkin Elmer) was added. The complete probe mixture was incubated 
for 4 hours at room temperature (22-25ºC) and then the reaction was stopped with 45 
microliters stop buffer (20mM NaCl, 50mM EDTA, 20mM Tris, 1% SDS)  
Table 9: Primers Used for Sequence comparison 
 
 
 
 
 
 
 
 
 
 
 
 
Primer Name Sequence 
U11F 5’-TCACGACGCGATCGCTGACTCGC-3’ 
U11R 5’-ATGGATCTGCAAAGACATCCGATTCCG-3’ 
U15F 5’-CGCAGAACCAGACGCTCAACGG-3’ 
U15R 5’-ACGGAGAGCTGTCGTGCTGAGCGG-3’ 
U18F 5’-CTAACGACACTGGGAATGAACGCTA-3’ 
U18R 5’- CTCTTGATGCATGTGGCAATTGCTGG-3’ 
U20F 5’-CTGCAACATGCGCGCCAGTTCATCACCGG-3’ 
U20R 5’-GGCCGTACCTTTCTTCGACGTG-3’ 
U31F 5’-CACGAAACAATGCGCCAGCATC-3’ 
U31R 5’-CGTCAAGAAGTTGTTACGGCTTG-3’ 
U38F 5’-TCACATTACCTCTGCAATAGCAG-3’ 
U38R 5’-CCTTCGTCTTCCGAGTCTCATGC-3’ 
U47F 5’-CCAGGTAGAGTTGCGTTAGCCTC-3’ 
U47R 5’-CATTGTGGTCAACTCACCCGACATG-3’ 
U79F 5’-CGTGCGCATAAAAGGACGTTG-3’ 
U79R 5’-CCCAATCAATTGGAACATTCTG-3’ 
U83F 5’-GAGAAGGTTAGTAATATGAGTG-3’ 
U83R 5’-CTCTCTCATGATAAACGCG-3’ 
U86F 5’-CCACGGCGAGATTGTTGATC-3’ 
U86R 5’-GCACACCACGCACAATCGG-3’ 
U90F 5’-CTGAATACTTGACATCTGTATAAGG-3’ 
U90R 5’-GCGGTGTCTCAATTTGCATC-3’ 
U91F 5’-CTTTGCAGAGATTCTCTGCTTGCAC-3’ 
U91R 5’-GTCACATCGATTGCATCCCATC-3’ 
U95F 5’-CCTATCGTTGCGCTGGGAATTCC-3’ 
U95R 5’-GGTAGATTGGATCCAACGGCCTTTTG-3’ 
U100F 5’-CAGAAAGGCCGTTGGATCCAATCTACC-3’ 
U100R 5’-CCGTCGTCATAGGATCTGTTTCGCG-3’ 
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Prehybridization & Hybridization  
The nitrocellulose membrane with the immobilized DNA was incubated in 10ml 
prehybridization buffer at 42º C with rocking for 10-30 minutes. While the membrane 
was being incubated, 10ml of the hybridization buffer was boiled with the α32P labeled 
probe. The membrane was then incubated with the hybridization/probe mixture for 16 
hours at 42ºC with gentle rocking. 
Table 10: Prehybridization and Hybridization Buffers for Southern Blot  
 Prehybridization Hybridization 
Formamide 25ml 25ml 
20x SSC 12.5ml 12.5ml 
50x Deinhardt’s Solution 5ml 1ml 
Sonicated salmon sperm 
DNA 
2.5ml 0.5ml 
1M NaPO4 2.5ml 0.75ml 
20% SDS 0.25ml 0.25ml 
Dextran sulfate N/A 10ml 
Water 2.5ml N/A 
 
Following incubation, the membrane was washed three times in a heated wash 
buffer (55-60ºC) containing 0.1x SSC, 0.1% SDS solution. The washed membrane was 
wrapped in plastic wrap and exposed to a phosphoimager screen for 4 hours- 5 days. 
The image was developed using a GE Typhoon Imager.  
Alignment of nucleotide sequences 
Complete alignment of nucleotide sequences was performed using ClustalX 
2.0.10. Parameters were as follows for pairwise alignments: Gap opening 10, Gap 
extend 0.1, Protein weight matrix Gonnet 250, DNA weight matrix: IUB.  For multiple 
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alignments: Gap opening g10, Gap extend 018.2, Delay divergent sequence 30%, DNA 
transition 0.5, Gonnet series, DNA weight matrix: IUB.  
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RESULTS 
 
 
Note to Reader 
Portions of this chapter have been previously published in Journal of Medical 
Virology, 2013, 85(11): 1940-1946 and has been reproduced with permission from 
Wiley Periodicals, Inc. 
AIM 1: Test the Ability of Various Compounds to Cause Reactivation of Integrated 
HHV-6 In Vitro  
Generation of HEK293 Single Cell Clones 
To develop an in vitro model of HHV-6 latency, HEK293 cells were infected with 
HHV-6A U1102. By limited dilution, single cell clones were isolated in individual wells of 
a 96-well plate and expanded. Although multiple single-cell clones were generated, 
some clones stopped dividing for an unknown reason.  Originally 50 viable single 
HEK293 cells were isolated, and ten of these were initially positive for HHV-6. However, 
seven of the clones lost the viral genome after prolonged subculturing. Three clones 
stably maintained the HHV-6A genome, as indicated by PCR amplification of ORF U94, 
as reported previously (15). The viable clones were designated C8, D2, and G6. As an 
additional means of confirming HHV-6 integration, fluorescent in situ hybridization 
(FISH) was performed using cosmid probes specific to large regions of the HHV-6 
genome. FISH for all three clones revealed hybridization of HHV-6 at the ends of 4',6-
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diamidino-2-phenylindole (DAPI) stained metaphase chromosomes, confirming viral 
integration into the telomere ends of the chromosomes (Figure 6). Two clones, D2 and 
G6 had one integration site; the final clone C8 had two integration sites (Figure 6).  
 
Figure 6: Fluorescent In Situ Hybridization of HEK293 Clones Infected with HHV-
6A.  Metaphase chromosomes of three HEK293 single cell clones with integrated HHV-
6 were stained with DAPI (blue). In this figure, hybridization was performed with HHV-6 
cosmid probes pMF311-12 and pMF335-631 which were labeled with fluorescein 
(green).  
 
Detection of Circularized Viral Genome During Reactivation 
Both HHV-6A and HHV-6B preferentially integrate into the telomeres as a means 
of establishing latency (15,18). The ability to reactivate from latency is essential to the 
spread of viral infection. To investigate the effect of epigenetic modifiers on the 
replication states of latent HHV-6 virus, HEK293 single cell clones were treated with 
varying concentrations of trichostatin A, sodium butyrate, valproic acid, or 
carbamazepine for three days. Once cytopathic effect was observed, DNA was isolated 
from the treated cells. To confirm the reactivation of integrated virus, a PCR-based 
assay was developed to detect the circularized HHV-6 genome. The designed primers 
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were specific to the unique length of the viral genome and oriented in opposite 
directions. Therefore, a PCR product would only be generated in the event that 
circularization of the viral genome occurs. Southern blotting was then performed on the 
PCR generated products using either and probed with an α32P labeled probe 
surrounding the viral DRs or with an α32P HHV-6A BAC vector probe. 
Initially, all three single cell clones were treated for three days with varying 
concentrations (160 ng/ml, 80 ng/ml, 40 ng/ml, 20 ng/ml or 10 ng/ml) of TSA or the 
other epigenetic modifiers, sodium butyrate, valproic acid, or carbamazepine to 
determine their ability to reactivate from the integrated form. Southern blotting and 
hybridization with radiolabeled BAC vector probe revealed that of the three clones, only 
the D2 clone was capable of reactivation, as indicated by the variation in banding 
patterns after development of the Southern Blot (Figure 7). Furthermore, of the 
epigenetic modifiers tested, only TSA induced the reactivation of latent HHV-6A virus 
(Figure 8). These results indicate that in some cases integration of HHV-6 may be a 
dead end phenomenon. Possible explanations for this will be presented in the 
discussion. 
To qualitatively asses the variation in size of the direct repeat during HHV-6 
reactivation, Southern blotting was performed on TSA-treated D2 clone as described 
above; however, a probe specific to the unique regions of the viral genome surrounding 
the DRs was used. Upon induction, with variable concentrations of TSA, multiple distinct 
bands were detected after hybridization. Differences in DR size at each TSA 
concentration demonstrate that upon circularization there is variation in the DR length 
(Figure 9). Possible reasons for this will be discussed at a later point. 
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Figure 7: Trichostatin A Effectively Induces the Reactivation of HEK293 Clone D2. 
HEK293 single cell clones (C8, D2, or G6) latently infected with HHV-6A were treated 
with varying concentrations of TSA (Lane 1: 160 ng/ml, Lane 2: 80 ng/ml, Lane 3: 40 
ng/ml, Lane 4: 20 ng/ml, Lane 5: 10 ng/ml Lane 6: untreated). Following induction, PCR 
was performed to detect the formation of viral concatemers. PCR products were 
separated by electrophoresis, blotted onto nitrocellulose and probed with a α32P HHV-
6A BAC vector probe. 
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Figure 8: TSA is Most Effective at Inducing the Reactivation of Latent   HHV-6 
Virus. HEK293 cells latently infected with HHV-6A were treated with varying 
concentrations of four epigenetic modifiers: sodium butyrate, carbamazepine, 
Tricostatin A, and valproic acid. (Lane 1: 160 ng/ml, Lane 2: 80 ng/ml, Lane 3: 40 ng/ml, 
Lane 4: 20 ng/ml, Lane 5: 10 ng/ml Lane 6: untreated). Following induction, PCR was 
performed to detect the formation of viral concatemers. PCR products were separated 
by electrophoresis, blotted onto nitrocellulose and probed with α32-dATP HHV-6A BAC 
vector probe. 
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 Figure 9: During Reactivation DR length is Variable.  Uninfected HEK293 or 
HEK293 cells latently infected with HHV-6A were treated with varying concentrations of 
TSA (160 ng/ml, 80 ng/ml, 40 ng/ml, 20 ng/ml or 10 ng/ml) or left untreated. Following 
induction, PCR was performed to detect the formation of viral concatemers.  
Additionally, the concatemer-formation assay was also performed on lytic infected or 
uninfected Jjhan T-cells.  PCR products were separated by electrophoresis, blotted onto 
nitrocellulose and probed with a α32-dATP DR probe. 
 
AIM 2: Test if Inherited HHV-6 in Patient Samples can be Reactivated In Vitro 
Reactivated virus is infectious 
In vitro experiments with HEK293 clearly demonstrated that HHV-6 can be 
reactivated from its latent form in HHV-6A containing cell lines. In the second aim of this 
project, the goal was to test if inherited HHV-6 in patient samples could be reactivated in 
vitro. Here, we used T-cells isolated from a patient with inherited HHV-6 who resides in 
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the United States. In a previous publication, confirmed HHV-6 integration at 18q23 and 
vertical transmission of the virus from parent to this patient, who was previously 
designated Family 1/Sibling 2 (15). In attempts to induce the inherited virus, PBMCs 
isolated from whole blood obtained from Family 1/Sibling 2 were treated with TPA and 
hydrocortisone, a combination previously shown to reactivate integrated HHV-6, while 
having limited amounts of toxicity (15). During induction, the treated PBMCs were co-
cultured with Jjhan or Molt3 T cell lines until primary cells reached their replication limits 
and died. Co-cultured cells were observed for visible cytopathic effect. As a control, 
PBMCs latently infected withU1102 were also induced with TPA and hydrocortisone. 
Visible cytopathic effect indicates that the induced virus is infectious (Figure 10). 
Reactivated virus is distinct from HHV-6A U1102 
The reactivated virus from Family 1/Sibling 1 was confirmed to be an HHV-6A 
strain by PCR analysis. In primary molecular analysis, the reactivated viral genome was 
compared to the HHV-6A U1102 laboratory stain. Restriction enzyme digestion and 
Southern blot analyses indicated that the viral genome was similar, but distinct from the 
U1102 strain. When probed with a radiolabeled BAC vector, a unique restriction pattern 
was observed, although the majority of visualized bands were colinear to the U1102 
fragments (Figure 11). 
Nucleotide and amino acid characterization of the reactivated virus 
To fully characterize the reactivated viral genome, we performed pyrosequencing 
on the isolated virion DNA. The generated consensus sequence was assembled using 
the HHV-6A U1102 genome as a reference. However, there were gaps in the nucleotide 
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 Figure 10: TPA/hydrocortisone Induced Virus from Patient PBMCs is Infectious. 
PBMCs latently infected with HHV-6 were treated with 10ng TPA /Hydrocortisone and 
co-cultured with uninfected T-cells. Visible cytopathic effect indicates that the induced 
virus is infectious.  
sequence, most notable in the regions surrounding the repetitive elements in the viral 
genome. As needed, select open reading frames were cloned and sequenced to 
complete the nucleotide sequence. Amino acid sequences were deduced using the 
Expasy translate tool, and both nucleotide and amino acid sequenced were aligned 
using Clustal Omega. In this study, the reactivated viral genome was compared to HHV-
6A U1102, HHV-6A GS, and HHV-6B Z29. 
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 Figure 11: Reactivated Virus Isolated from Family 1/Sibling 2 is Distinct from 
HHV-6A U1102. Virion DNA isolated from the PBMCs of Family 1/Sibling 2 and HHV-6A 
U1102 were digested using SacI and BamHI. Fragments were separated by 
electrophoresis, blotted onto nitrocellulose and probed with a radiolabeled HHV-6A 
U1102 BAC clone.  
The nucleotide sequence generated by pyrosequencing was 156.6 kbp in length. 
This length was comparable to the HHV-6AGS which is 156.9 kbp in length. BothHHV-
6A GS virus and this reactivated virus were shorter than the HHV-6A U1102 genome 
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and the HHV-6B Z29 genome, that are 159.3kbp and 162kbp, respectively. Similar to 
reports comparing HHV-6A U1102 to HHV-6B Z29, there was noted divergence in the 
length of the repetitive regions within the viral genome. The reactivated virus was found 
to have a shortened DRL and DRR when compared to U1102, GS, and Z29. However 
when compared to HHV-6A GS, the R3 region, located between open reading frame 
U91 and U94, was approximately 300bp longer. On the other hand, the repetitive R1/ 
R2 and R3 of HHV-6AU1102 were approximately 250bp and 420bp longer than the 
reactivated virus, respectively. 
Previous publications have thoroughly covered the difference in nucleotide and 
amino acid sequence between the HHV-6A U1102 and HHV-6B Z29 strain (5,6). To 
evaluate the level of interstrain variation, we focused on analyzing the differences 
between the reactivated virus and the two HHV-6A strains, GS and U1102. The 
reactivated was more closely related to the GS (>99% nucleotide identity) isolate than 
U1102 (97% nucleotide identity). At the nucleotide level, all open reading frames were 
greater than 99% identical to the HHV-6A GS. Of the 83 open reading frames analyzed, 
only eleven genes had predicted amino acid sequences that were identical for the 
reactivated virus and both HHV-6A laboratory strains (Table 11). Interestingly, three of 
these genes are neither located within the herpesvirus core gene blocks, the 
betaherpesvirus gene block, nor conserved between Roseoloviruses. These genes 
were U47A, U60, and U63. The lack of divergence suggests they may be important to 
the biological properties of the HHV-6A viruses. These genes will be further discussed 
at a later point. The nucleotide identity between GS and the reactivated virus ranges 
from 99 to 100%, while the amino acid identity ranges from 97 to 100%. The nucleotide 
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identity between the U1102 and the reactivated virus ranges from 97% to 100%, while 
the nucleotide identity ranges from 92% to 100% (Table 12). Interestingly, the predicted 
U18 envelope glycoprotein and the predicted U20 membrane protein nucleotide 
sequences had early stop codons. The predicted U18 amino acid sequence was 66 
amino acid shorter than HHV-6A GS and predicted for HHV-6A GS and U1102, while 
the U20 amino acid sequence was 188 shorter than the HHV-6 GS and U1102 strains 
(Figure 12 & 13).  
 
Table 11: Open Reading Frames with 100% Identity Between Reactivated Virus, 
HHV-6A GS and HHV-6A U1102 
Open Reading Frames with 100% Amino Acid Identity   
Gene ID Gene Product Conserved  
Gene?  
U24A Protein U24A Yes 
U25 Tegument protein UL43 Yes 
U29 Capsid triplex subunit 1 Yes 
U32 Small capsid protein Yes 
U35 DNA packaging protein UL33 Yes 
U47A Envelope glycoprotein 24 No 
U48 Envelope glycoprotein H Yes 
U56 Capsid triplex subunit 2 Yes 
U60 DNA packaging terminase subunit 1 No 
U63 Protein UL92 No 
U75 Tegument protein UL7 Yes 
 
The Virus Reactivated from Patient PBMCs Differs from the Inherited Virus.  
Previous reports indicate that HHV-6 may be reactivated from its inherited form (15,36). 
In this study, five open reading frames (U11, U18, U20, U47, and U91) were cloned and 
sequenced using genomic DNA isolated from whole blood obtained from Family 
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1/Sibling 2 as template. To determine if the inherited virus was induced by 
TPA/hydrocortisone treatment, we compared the reactivated virion DNA sequence and 
the genomic DNA sequences. In all cases, the reactivated sequences differed from the 
inherited sequences (Table 13). Of the genes studied, the immunodominant U11 
tegument protein and the U91 membrane protein had the greatest difference when 
compared to the inherited virus. Variation in nucleotide sequence indicates that this 
individual presenting with CFS-like symptoms harbored an HHV-6 strain distinct from 
the virus which was inherited by germline transmission. 
Table 12: Most Divergent Open Reading Frames When Comparing the Reactivated 
Virus to HHV-6A GS and HHV-6A U1102 
 
Nucleotide 
Identity  
  
Amino Acid 
Identity   
  
GS U1102 GS U1102 
Gene 
ID  Putative Function 
U11 Tegument protein pp150 99.7 97.8 99.3 95.4 
U17 Tegument protein vICA 100.0 99.0 100.0 98.5 
U18 
Envelope glycoprotein 
UL37 99.6 97.6 99.1 95.2 
U19 Protein UL38-anti-apoptotic 99.6 98.1 99.0 96.7 
U20 Membrane protein U20 99.9 98.8 97.0 94.4 
U24 Protein U24 100.0 97.7 100.0 96.6 
u31 Large tegument protein 99.97 99.49 94.85 97.68 
u47 Envelope glycoprotein O 99.95 98.44 93.8 97.25 
U46 Envelope glycoprotein N 100.0 98.4 100.0 96.4 
U62 Protein UL91 100.0 98.5 100.0 96.5 
U76 Capsid portal protein 100.0 99.7 100.0 96.9 
U79 Protein UL112 100.0 96.4 100.0 92.2 
U90 Regulatory protein IE1 99.8 97.7 99.6 95.3 
U91 Membrane protein UL124 100.0 97.2 100.0 93.5 
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 Figure 12: Nucleotide Alignment of U18 Envelope Glycoprotein Sequences. PCR-
amplified HHV-6 glycoprotein U18 was TA cloned and sequenced. Obtained nucleotide 
sequences were translated using Expasy Translate and aligned using Clustal Omega.  
 
AIM 3: Test the Efficacy of Antiviral Treatment in Suppression of HHV-6 
Reactivation/Replication 
Prevalence of CIHHV-6 in Cohort of Patients with Neurological Symptoms 
To reveal the prevalence of CIHHV-6 in 337 US patients suffering from a wide 
range of CFS-related neurological symptoms, including long term fatigue, peripheral 
blood samples were tested by quantitative PCR by Viracor-IBT laboratories, Inc. Seven 
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patients had higher than 0.5 million HHV-6 copies per ml of blood. A two-tailed Fisher 
exact test was used to determine the significance of CIHHV-6 prevalence among these 
patients. The CIHHV-6 rate among this cohort of US adult patients suffering from CFS 
patients suffering from neurological symptoms was 2.1% (7/337). This is significantly 
greater (p=.03) than the expected value of 0.8% reported in the general US population 
(34,64). 
CFS Patients with CIHHV-6 Express Viral mRNAs, and Long Term Antiviral 
Treatment Abrogates Viral mRNA Production 
The four patients enrolled in this study harbored over 0.5 million copies of HHV-6 
DNA copy numbers per ml of peripheral blood. Patients presented with a variety of 
neurological symptoms including but not limited to headache, blurred vision, and 
memory impairment, as well as other symptoms such as generalized pain and long term 
fatigue.   
To determine if the symptoms correlated with replicating HHV-6, nested RT-PCR 
was employed to detect the late envelope glycoprotein U100 mRNA in whole blood 
samples from patients with CIHHV-6 (93). Initial RT-PCR assays were performed on 
blood samples isolated from symptomatic patients prior to the administration of antiviral 
medications, and follow-up samples were taken during or after treatment. For each RT-
PCR reaction, 5ng of total RNA isolated from peripheral blood was used. In all cases, 
U100 mRNA was detected in blood samples, in the absence of antiviral treatment 
(Figure 14, 15, 16). On the other hand, ten control single donor samples obtained from 
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 U20 Membrane Protein  
 AA Length  % Identity  
Reactivated  234   
HHV-6A GS  422  97.01  
HHV-6A U1102  422  94.44  
 
Figure 13: Nucleotide Alignment of U20 Membrane Protein Sequences. PCR-
amplified HHV-6 glycoprotein U20 was TA cloned and sequenced. Obtained nucleotide 
sequences were translated using Expasy Translate and aligned using Clustal Omega.  
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Table 13: Nucleotide Comparison: Inherited vs. Reactivated Virus 
Gene ID  Mismatches/Total nucleotides  % Difference  
U11  87/2616  3.1  
U18  16/882  1.81  
U20  16/1268 1.34 
U47  31/1858  1.46 
U91  21/564 2.84  
 
the local blood bank were negative for U100 mRNA (data not shown). In the absence of 
reverse transcriptase, PCR products were not detected. Long term (≥six weeks) 
administration of foscarnet (patient 4) or valganciclovir (patient 3) resulted in the 
abrogation of U100 mRNA expression (Figure 15 and 16), while short term (three 
weeks) administration of valganciclovir was not sufficient to eliminate viral gene 
expression in two unrelated patients (patients 1 and 2) (Figure 14). Five weeks after the 
cessation of intravenous foscarnet treatment (patient 4), U100 mRNA was detected in 
the whole blood of patient 4. In all cases, resolution of symptoms was concurrent with 
the reduction of mRNA expression. This suggested that U100 mRNA detection is a 
reliable method of detecting HHV-6 persistence. However, treatment efficacy was 
variable and appears to be dependent on the length of treatment, with treatment length 
of greater than or equal to six weeks being optimal for valganciclovir and foscarnet. 
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The Late U100 viral mRNA may Originate from an Exogenous HHV-6 Strain 
Amplified U100 cDNA was sequenced to confirm that the RT-PCR products were 
derived from mature mRNA that lacks introns rather than the inherited viral DNA. 
Sequencing was also performed to determine if the detected mRNA originated from the  
 
Figure 14: Amplification of Envelope Glycoprotein U100 mRNA after Three Week 
Valganciclovir Treatment.  Nested reverse transcriptase PCR was used to amplify 
HHV-6 glycoprotein U100 mRNA from whole blood. Total RNA was converted to cDNA 
and two rounds of PCR were performed. Second round PCR products were separated 
by agarose gel electrophoresis, stained with ethidium bromide, and visualized using UV 
light. Top U100 RT-PCR (Lane 1: 100bp Ladder, Lane 2: Patient 1, before treatment, 
Lane 3: Patient 1, 3 weeks  post treatment, Lane 4: Patient 2, before , Lane 5: Patient 2, 
3 weeks  post treatment, Lane 6: negative control (Molt3 T-cells). Lane 7: positive 
control Molt3 T-cells infected with HHV-6A U1102. Bottom: Beta-actin RT-PCR) 
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Figure 15: Amplification of Envelope Glycoprotein U100 mRNA after Long Term 
Valganciclovir Treatment.  Nested reverse transcriptase PCR was used to amplify 
HHV-6 glycoprotein U100 mRNA from whole blood. Total RNA was converted to cDNA 
and two rounds of PCR were performed. Second round PCR products were separated 
by agarose gel electrophoresis, stained with ethidium bromide, and visualized using UV 
light. Top U100 RT-PCR (Lane 1: 100bp Ladder, Lane2: Patient 3, before treatment, Lane 
3: Patient 3, 6 weeks post treatment, Lane 4: Patient 3, 12 weeks post treatment , Lane 
5: negative control (Molt3 T-cells), Lane 6: positive control (Molt3 T-cells infected with 
HHV-6A U1102). Bottom: Beta-actin RT-PCR. 
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 Figure 16: Amplification of Envelope Glycoprotein U100 mRNA after Long Term 
Foscarnet Treatment.  Nested reverse transcriptase PCR was used to amplify HHV-6 
glycoprotein U100 mRNA from whole blood. Total RNA was converted to cDNA and two 
rounds of PCR were performed. Second round PCR products were separated by 
agarose gel electrophoresis, stained with ethidium bromide, and visualized using UV 
light. Top U100 RT-PCR (Lane 1: 1kb Ladder, Lane2: Patient 4, before treatment, Lane 3: 
Patient 4, 6 weeks post treatment, Lane 4: Patient 4, 5 weeks after cessation of 
treatment, Lane 5: negative control (Molt3 T-cells), Lane 6: positive control (Molt3 T-
cells infected with HHV-6A U1102). Bottom: Beta-actin RT-PCR. 
 
inherited virus, or from an exogenous virus. The U100 gene of the inherited viral 
genome was also amplified and both cDNA and inherited HHV-6 DNA sequences of 
U100 were cloned and sequenced. For sequences from the inherited viral DNA 
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fragments, introns were removed using previously accepted splice sites prior to 
alignment using ClustalW2. Isolated cDNA sequences were also compared to the U100 
sequences for HHV-6A U1102 and GS, or HHV-6B Z29. All patient cDNA sequences 
were more similar to HHV-6A U1102 than HHV-6A GS and differed from HHV-6A 
U1102 by only a CG inversion at bases 193/194 (Figure 17). On the other hand, the 
inherited genomic sequences were more similar to HHV-6A GS. The inherited HHV-6A 
sequences were greater than 99% identical to each other for three patients, as were all 
the reactivated viral sequences. 
The cDNA and inherited genomic sequences differed from each other in all 
cases. U100 cDNA shared only an average of 96.3% nucleotide sequence identity with 
the inherited HHV-6A viral genome. U100 cDNA from patient 1 was more similar to 
HHV-6A U1102, while the inherited HHV-6 DNA sequence was 98% identical to HHV-
6B Z29 (Figure 17). In addition, the U100 mRNA sequence and inherited viral DNA 
sequences shared only a 90% nucleotide sequence identity (Figure 18). Differences in 
the genomic DNA and cDNA sequences demonstrate that these symptomatic patients 
with inherited HHV-6 harbor more than one HHV-6 virus, and the U100 mRNA detected 
by RT-PCR originates from an exogenous virus. 
Inherited HHV-6 Viral Genome Sequences are Heterogeneous 
Our results clearly indicated that the reactivated virus from these patient samples 
did not emanate from the major inherited virus. In all cases the reactivated viruses were 
more similar to HHV-6A U1102 than HHV-6A GS. Additionally, there was a high level of 
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similarity between the U100 DNA sequences of the inherited viruses. To compare the 
genome of the inherited HHV-6 viruses to the HHV-6A GS virus, we performed  
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Figure 17. Nucleotide Alignment of cDNA and Genomic Sequences Compared to 
HHV-6 Laboratory Strains. PCR amplified HHV-6 glycoprotein cDNA or corresponding 
genomic DNA fragments were TA cloned and sequenced. Obtained sequences were 
aligned using the Mauve algorithm and visualized in JalView in the ViPr database. 
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 Figure 18. Nucleotide Alignment of cDNA and Genomic Sequences for Patient 1.  
PCR amplified HHV-6 glycoprotein cDNA or corresponding genomic DNA fragments 
were TA cloned and sequenced. Obtained sequences were aligned using Clustal 
Omega. 
 
restriction fragment length analysis on DNA from four patient’s PBMCs or GS virion 
DNA. 
Briefly, DNA was subjected to restriction enzyme digestion using SacI; fragments 
were separated by electrophoresis, blotted onto nitrocellulose and probed with a 
radiolabeled HHV-6A U1102 BAC clone (Figure 19). Despite similarities among the 
inherited HHV-6 sequences, Southern blot hybridization showed distinct banding 
patterns for each inherited virus and a significantly diverged banding pattern from HHV-
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6A GS, indicating that all inherited viruses evaluated in this experiment markedly differ 
from HHV-6A GS and are also uniquely distinct from each other.  
 
 
Figure 19: Restriction Fragment Analysis of Inherited HHV-6 Viruses. Cellular DNA 
from patient PBMCs or virion DNA from HHV-6 GS was digested using SacI. Fragments 
were separated by electrophoresis, blotted onto nitrocellulose and probed with a 
radiolabeled HHV-6A U1102 BAC clone. Lane 1: HHV-6A GS virion DNA, Lane 2: 
patient 5, Lane 3: patient 3, Lane 4: patient 4, Lane 5: patient 6; patient 6 is from Family 
1, Sibling 2 (15,18). 
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DISCUSSION 
 
 
Note to Reader 
Portions of this chapter have been previously published in Journal of Medical 
Virology, 2013, 85(11): 1940-1946 and has been reproduced with permission from 
Wiley Periodicals, Inc. 
Latency of HHV-6 
In the first part of this study, single cell HEK293/HHV-6A clones were established 
in vitro. Interestingly, HHV-6A infected HEK293 cells could be segregated into three 
groups: (1) cells that stopped replicating after HHV-6 infection, (2) cells that continued 
replicating after HHV-6 infection that were initially PCR positive for HHV-6A and later 
lost the viral genome and (3) cells that were infected with HHV-6A and maintained the 
viral genome in the telomeres, as evident by FISH analysis. These results were 
unexpected and indicate areas that need to be addressed in the future.  
HEK293 cells are positive for telomerase, a reverse transcriptase that extends 
the 3’ ends of chromosomes (126); however, replicative senescence followed HHV-6 
infection in some HEK293 infected single cell clones. This suggests that HHV-6 
integration may abrogate telomerase activity in specific chromosomes. Alternatively, 
HHV-6 integration may lead to telomere instability and lead to senescence if integration 
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of the viral genome occurs in a region of the human genome essential for cell division, 
or for other unknown reasons. 
Subtelomeres are transcribed by RNA polymerase II into non-coding RNA known 
as TERRA (telomeric repeat-containing RNA) (127). TERRA, exclusively located in the 
nucleus, plays a role in heterochromatin formation, but also induces telomere (128,129). 
TERRA molecules are similar in sequence to telomeric DNA and competes with 
telomeres for telomerase binding (128). Furthermore, TERRA induces telomere 
shortening by stimulating the expression of exonuclease 1 expression at chromosome 
ends (128,129). Insertion and transcription of the entire HHV-6 genome into the 
subtelomere may indirectly stimulate TERRA transcription and lead to telomere 
shortening. This effect, however, may vary depending on the site of integration. 
Unfortunately, due to large amounts of chromosomal rearrangements in HEK293 cell 
lines, FISH analysis was not able to identify the specific site of integration for 
HEK293/HHV-6A single cell clones. The effect of HHV-6 integration on TERRA 
transcription and telomerase activity in vivo in infected patients has not been 
investigated, but is an interesting and important subject which should be explored. 
Loss of the viral genome after subsequent growth in cell culture was also noted 
in seven of the ten originally established HEK293/HHV-6A single cell clones. We 
hypothesize that if the viral genome integrates close to the physical end of the 
chromosome, rapid loss of HHV-6 genome may occur due to end replication problems. 
Failure to maintain the viral genomes close to the end of the chromosome may also be 
related to the loss of telomerase function proposed previously, with the affected cell 
eventually losing the viral genome. 
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The third outcome, maintenance of the viral genome over time, shows that 
HEK293 cells can be used as an in vitro model for HHV-6 infection, latency, and 
reactivation. There have been no in vitro HHV-6 models established thus far. This 
model will prove useful for testing of recombinant/mutant of HHV-6 strains in vitro, and 
the effect of individual viral genes on the viral integration and reactivation. 
Reactivation of HHV-6 
An additional phenotypic difference seen with HEK293/HHV-6A clones was the 
inducibility with epigenetic modifiers TSA, sodium butyrate, carbamazepine, or valproic 
acid. Of the three clones tested, only one was inducible, and of the epigenetic modifiers 
inhibitors only TSA was capable of inducing viral reactivation from its integrated form. 
All of the epigenetic modifiers tested are histone deacetylases (HDACS). Histone 
deacetylation results in compaction of heterochromatin and the repression of 
transcription; thus, inhibition of HDACs typically leads to an increased gene expression. 
The most probable explanation for differences observed in the efficacy of the HDAC 
inhibitors is specificity. HDACs fall into five classes. Four of the classes include the 
classical or zinc-dependent HDACS (Table 14). The class III HDACs are made up by 
the sirtuin family of proteins. None of the HDAC inhibitors tested in this study were 
active against class III HDACs. However, TSA inhibits all zinc-dependent histone 
deacetylases (class I, IIa, IIb, and IV); while the other HDAC inhibitors tested are more 
specific (130,131). Valproic acid sodium butyrate acid specifically inhibits class I and IIa. 
Carbamazepine has some selectivity against class I, IIa, and IIb, but to date has only 
been shown to be active against three HDACS: HDAC3, 6, and 7 (132,133).  
65 
 
When HEK293/HHV-6A single cell clones were treated with TSA, reactivation 
resulted in concatemer formation by PCR amplification and Southern blot hybridization 
(Figure 19). Interestingly, during reactivation the length of the direct repeat was variable 
as indicated by the presence of different sized bands when the Southern blot was 
probed with a radiolabeled DR probe. The DR regions of the viral genome are variable 
and ranges in size from 8kbp to 13kbp, with up to 1kbp of this being comprised of 
Table 14: Zinc-dependent Histone Deacetylases (130,131). 
Class HDAC Localization 
Class I HDAC1 Nucleus 
 HDAC2 Nucleus 
 HDAC3 Nucleus 
 HDAC8 Nucleus 
Class IIa HDAC4 Nucleus/cytosol 
 HDAC5 Nucleus/cytosol 
 HDAC7 Nucleus/cytosol 
 HDAC9 Nucleus/cytosol 
Class IIb HDAC6 Nucleus/cytosol 
 HDAC10 Nucleus/cytosol 
Class IV HDAC11 Nucleus/cytosol 
 
telomere repeats. Presumably, homologous recombination may occur at any location 
within the telomere-like repeats; thus, this is one probable explanation for the variation 
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in DR length seen after circularization. It is also possible that there deletions occur in 
the DR region during viral reactivation, as the smallest size DR detected by Southern 
Blot is about half the size of the HHV-6 DR length previously recorded in the literature 
(5,6,9). Large deletions of up to 5.4kb at internal regions in the internal regions of the 
DRs have been observed during passage of HHV-6 viruses in T-cell in vitro (134), 
resulting in DR lengths similar to those seen in this study. The exact regions of deletions 
have not been elucidated in this study, but could be accomplished by cloning and 
sequencing of the PCR amplified products. 
Proposed Mechanism of HHV-6 Latency & Reactivation 
It has been well established that HHV-6 establishes latency in vitro by integration 
into the telomeres of host chromosomes. In order for homologous recombination to 
occur, DNA strands must be cleaved. The most probable candidate for this activity is 
theHHV-6 protein U94, which is homologous to the Rep78/68 protein of the adeno-
associated virus type 2(AAV-2). AAV-2 and HHV-6 are similar in that both specifically 
integrates into the host chromosomes, however, AAV-2 integration has only been found 
to occur in chromosome 17 and integration occurs in a region outside of the telomere. 
The Rep78/68 is important for AAV-2 integration and possesses DNA binding, 
endonuclease, and helicase activity. The HHV-6 protein U94 has confirmed DNA 
binding activity and complements the activity of Rep deficient viruses and likely 
performs a similar function((135,136). However, to date there are no reports of 
endonuclease and helicase activity for this protein. 
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The model proposed here for integration and latency begins with cleavage of the 
viral telomere repeats by protein U94. Following cleavage, strand exchange and 
homologous recombination would occur, resulting in the integration of the entire viral 
genome into the subtelomere of the host chromosome. In this study, TSA was shown to 
induce the reactivation of latent HHV-6 from its integrated form; we propose that TSA 
treatment leads to the expression of a viral gene, which we propose is protein U94, 
which aids in excising the viral genome from the subtelomere and facilitates  
circularization of the viral genome. Replication of the circular intermediate results in the 
formation of concatemers of the viral genome (Figure 20). 
Nucleotide and Amino Acid Variation of HHV-6 
An HHV-6A virus isolated from Family 1/Sibling and completely sequenced was 
compared at the nucleotide and amino acid level to both HHV-6A GS and U1102, and 
our results indicate that the virus is distinct from either of the HHV-6A strains which 
were previously sequenced. Analysis of the whole genome sequence results clearly 
indicate that some regions of the reactivated virus are highly conserved when compared 
to the two fully sequenced HHV-6A variants. Interestingly, the reactivated virus from 
Family 1/Sibling 2 was >99% identical to the HHV-6A GS strain. We suspect that the 
two viruses may be similar because of the geographic region of isolation. Both the 
reactivated virus and the GS strain were isolated in North America, while the U1102 
isolate was obtained from an individual in Uganda. The close sequence similarity 
between the GS virus and the Family 1/Sibling 2 virus, which were both isolated in 
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North America, and their divergence from the U1102 strain isolated in Uganda suggests 
that HHV-6 viruses may be further segregated into geographical subtypes. 
The current study indicates that intrastrain variation may be as high as 3% at the 
nucleotide level and 8% at the amino acid level, and this is higher than previously 
recognized variation. These differences may pose difficulties when designing PCR 
primers and may lead to failure to identify individuals with HHV-6 in routine clinical 
assays. The divergence seen between the core gene blocks and towards the right end 
of the genome are not surprising, as these regions of the genome seem to be hotspot 
for variation (5,6). These regions are most divergent when comparing HHV-6A strains 
and HHV-6B viruses. Nevertheless, high levels of conservation at some open reading 
may indicate biological significance and these genes may prove useful in development 
of HHV-6 PCR assays for detection. Three of the most highly conserved genes were not 
located in the herpesvirus core gene blocks and were not unique to roseoloviruses 
(Table 11): U47A, U60, and U63. No work has been done to characterize the function of 
either of these genes, and future studies should address this issue.  Open reading 
frame U47A is located immediately downstream of the hypervariable U47 gene region, 
and is presumed to encode an envelope glycoprotein. However, no work has been done 
to further characterize this gene. The U60 spliced late gene which encodes a DNA 
packaging terminase, is the most conserved gene when comparing HHV-6A and HHV-
6B viruses, although it is sometimes designated U66 in the B variants (5,6). Finally, U63 
is an uncharacterized protein, but relationship to HCMV UL92 has been proposed. CMV 
UL92 is a betaherpesvirus-specific gene that is essential for CMV replication in 
fibroblasts; however, it also has not been fully characterized (137). 
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Figure 20: Proposed Mechanism for HHV-6 Integration and Reactivation 
Homologous recombination between the host telomeres and viral telomeres are 
facilitated by the viral protein U94, which probably cleaves the viral telomeres to allow 
strand exchange and recombination.  Reactivation, induced by TSA, results in 
expression of viral genes, such as U94, that function to allow recombination of the viral 
telomere repeats and result in the circularization of the viral genome.  The circularized 
viral genome is replicated, and results in the formation of concatemers. 
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The predicted amino acid sequences of two proteins, U18 and U20, located 
between the betaherpesvirus core gene block and the first conserved herpesvirus core 
gene block, were shorter than the amino acid sequences for HHV-6A GS and U1102. 
The U18 envelope glycoprotein was 66 amino acids shorter than the amino acid for 
HHV-6A GS and HHV-6A U1102, and the U20 protein was 188 amino acids shorter 
than the laboratory strains, GS and U1102. Both of these proteins are preferentially 
expressed in HHV-6B chronically infected T-cell lines. However, the function of neither 
of these proteins in HHV-6A viruses has been fully characterized (138). Recent reports 
indicate that for HHV-6B viruses, U20 is involved in inhibition of tumor necrosis factor 
receptor induced apoptosis in infected cells (139). However, the function of U20 
encoded by HHV-6A, which bears only a 90% amino acid identity to HHV-6B U20, has 
not been investigated. The HHV-6A and HHV-6B U18, U19, U20 genes (previously 
named EJFL6, EJFL4, and EJFL3) differ in temporal regulation and splicing patterns. 
Both U18 or U20 may be expressed as full length proteins or a splice product of the 
three open reading frames may be produced (138,140). For HHV-6A, the U19 is 
excluded by splicing and produces a transcript shorter than the HHV-6B transcript 
(526bp vs 1.9kbp) expressed during the first 8 hours of infection, while the HHV-6B 
splice product is expressed up to 24 hours post infection. 
Inherited Herpesvirus Syndrome (IHS)  
Although inheritance of HHV-6 occurs infrequently, by using previously reported 
prevalence estimates approximately 2.5 million people in the United States have 
inherited the virus. This is a conservative estimate, as wide scale studies assessing 
prevalence have not been performed, and increased prevalence has been noted in 
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hospitalized individuals and individuals displaying neurological dysfunction (40,42–
49,86,92). The patients in this study represent a unique population of individuals with 
chronic fatigue syndrome that have inherited HHV-6. Approximately 1.25 million 
individuals in the United States suffer from chronic fatigue syndrome; if the CIHHV-6 
prevalence reported in this study holds true (over 2%), this unique population would be 
made up of more than 25,000 people. The increased CIHHV-6 prevalence in this 
population suggests a role of HHV-6 in CFS pathology. In support of this hypothesis, in 
this study we documented late viral mRNA production in all four unrelated patients with 
CIHHV-6 and chronic fatigue syndrome-like neurological symptoms. In contrast, viral 
mRNA was reported in only 8% of asymptomatic CIHHV-6 (34). 
Surprisingly, the sequence of the late mRNAs markedly differed from the 
inherited viral genome sequences in CIHHV-6 positive patients with CFS-like 
neurological symptoms. The presence of an exogenous persistently replicating HHV-6 
virus suggests that patients with CIHHV-6 exhibit immune tolerance or 
immunosuppression. It has been shown that the humoral response to inherited HHV-6 
differs from primary infection. A study by Tanaka-Taya et al. supports the notion of 
immune tolerance in CIHHV-6 patients (38). There, only 14% had detectable antibodies 
directed at glycoprotein B, the major neutralizing epitope, compared to 60% detection in 
healthy adult controls(38). Reduced gB titers suggest that individuals with CIHHV-6 may 
have a reduced ability to fight a secondary HHV-6 infection. Additionally, several studies 
of cellular response to HHV-6 indicate that there is a low frequency of circulating HHV-6 
responsive T-cells (105–107). Currently it is unclear if this phenomenon holds true for 
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individuals harboring CIHHV-6, but low frequency of responding T-cells may contribute 
to repeated HHV-6 infections. 
To date, there have been no studies on the rate of superinfection in patients with 
inherited HHV-6. This study suggests that, in symptomatic CIHHV-6 patients, infection 
with an exogenous HHV-6 virus may be a frequent occurrence. Additionally, we propose 
that superinfection is the differentiating factor between symptomatic and asymptomatic 
individuals with CIHHV-6; however, this was not directly investigated in this study. 
Taken together, we propose that some CIHHV-6 individuals acquire and are persistently 
infected with exogenous HHV-6 strains that lead to a wide range of neurological 
symptoms. We propose to name this condition inherited herpesvirus 6 syndrome or IHS. 
The virus isolated and sequenced from Family 1/Sibling 2 differed from the inherited 
virus at five open reading frames analyzed and this individual also suffered from CFS-
like neurological symptoms; according to the above criteria, this individual also suffers 
from IHS (Table 13). 
Results indicate that patient response to antiviral therapy using oral 
valganciclovir or intravenous foscarnet was largely dependent on treatment length. A 
three week treatment with valganciclovir was ineffective in preventing virus reactivation, 
as indicated by the recurrent expression of U100 mRNA. We recently documented the 
long-term benefit of antiviral drug therapy of two patients with IHS, one of which was 
Family 1/Sibling 2 (83). Both of these patients have suffered debilitating neurological 
symptoms but antiviral therapy resulted in marked and long-lasting improvement also 
documented by quantitative EEG (83). Years after cessation of antiviral therapy, we 
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were unable to detect detectable U100 mRNA in their PBMCs and these individuals are 
also free of neurological symptoms. 
 
Reactivation of Inherited HHV-6 
There have been previous reports of reactivation of integrated HHV-6. Arbuckle 
et al. 2010 demonstrated in vitro reactivation of integrated HHV-6 by chemical inducers, 
such as TPA and trichostatin. More recently, Gravel et al. reported the transmission of a 
CIHHV-6 strain transplacentally from mother to child, in the absence of inheritance 
(15,36). In the first, sequencing of the direct repeat and the U94 gene revealed that the 
reactivated and inherited viruses were identical (15). In the latter study, evidence for this 
transmission comes from nucleotide sequence comparison of a portion of the U39 
envelope glycoprotein B, and the presence of unique polymorphisms in the DNA 
sequences of both the mother and infant (36). Here, we employed a similar strategy by 
sequencing genomic DNA and cDNA isolated from the same patient. However, our 
results indicate that the detected mRNA arose from only an exogenous HHV-6 virus in 
all the patient samples evaluated, rather than the inherited viruses. We did not see 
evidence of reactivation of the CIHHV-6 virus. However, it is possible that this occurs as 
well and that the copy number is too low to be detected. Contradictions between this 
study and previously mentioned studies suggest that the ability of CIHHV-6 viruses to 
reactivate is a complex process, and may vary from one individual to another. 
Immunological status may play a role in the ability of individuals to be infected with 
exogenous HHV-6 or for the reactivation of the latent inherited virus. No studies have 
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conclusively shown the lack of neutralizing antibodies in CIHHV-6 individuals, and 
antibodies directed against the HHV-6 IE-A gene were detected at a higher rate in 
CIHHV-6 individuals (38). This indicates that some CIHHV-6 individuals are capable of 
mounting an immune response to HHV-6; these individuals may be less susceptible to 
continuous reactivation of the virus or reinfection by exogenous strains of the virus. The 
differences in observed immune responses may be due to the ability of the immune 
system of some individuals to override immune tolerance. Alternatively, the degree of 
differences between the sequence of dominant antigen epitopes of the inherited viral 
genes and contemporary virus isolates may also impact immune response. 
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FUTURE DIRECTIONS 
 
 
The current study demonstrated reactivation of integrated HHV-6 in in vitro 
models and the propensity for infection with exogenous HHV-6 strains in individuals with 
an inherited form of the virus. Although HHV-6 and its inheritance have been recognized 
by a number of studies, there are limited studies focusing on CIHHV-6 and the 
characterization of HHV-6 strains. Below are suggestions of future studies which are 
imperative for the understanding of HHV-6 latency and inheritance. 
Prevalence of CIHHV-6 in Neurological Disorders 
Large multi-site studies should focus on determining the prevalence of CIHHV-6 
in chronic fatigue syndrome and other neurological disorders. In this study, there is 
limited evidence that the rate of HHV-6 inheritance may be greater than the proposed 
0.8% in the United States population. Other studies have also demonstrated increased 
prevalence of inheritance in individuals hospitalized for a variety of conditions (40,42–
49). Many hospitals and research institutions have repositories of biological specimens 
and testing for CIHHV-6 is simple and cost efficient. 
Detection of CIHHV-6 can accomplished by quantitative real time PCR analysis 
performed on whole blood, hair follicle, and other biological specimens.   Amplification 
of the U67 open reading frame has previously been used as a means of determining 
CIHHV-6 prevalence (66) and will be used here. A result of greater than 106 viral copies 
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per ml would indicate inheritance of the virus.  Prevalence will be calculated by dividing 
the number of inherited cases by the total number of samples tested. Statistical 
significance will be determined using the Fisher’s Exact test, as described previously 
(66). 
Cellular and Humoral Responses to HHV-6 in CIHHV-6 Individuals 
Future studies should evaluate cellular and humoral response to HHV-6 in 
individuals with an inherited form of the virus. More recently, several research groups 
have focused on the cellular and humoral response to HHV-6 (105,107,141). However, 
none of these studies have evaluated these responses in individuals with an inherited 
form of HHV-6. This is an important area of research which needs to be addressed in 
the near future, considering the implications of the current study. One of the most 
variable genes noted in sequencing study was U11, an immunodominant tegument 
protein (Table 13). A recently published article looked at the antibody response to this 
protein in individuals suffering from CFS and found no differences in antibody response 
when compared to healthy controls (88). However, one limitation of this study is that it 
failed to look at individuals with an inherited form of the virus.   
PBMCs will be isolated from CIHHV-6 or non-CIHHV-6 individuals by density 
gradient centrifugation (Lymphoprep) and maintained in RPMI-1640 medium with 10% 
FBS and 50µg/ml gentamicin. For T-cell expansion cells will be maintained in culture 
medium containing phytohaemagglutinin (20μg/million cells) and 50U/ml interleukin-2. A 
Low HHV-6 specific T-cell frequency has previously been reported (105–107), therefore, 
ex vivo expansion with HHV-6 antigen may be necessary prior to functional assays. 
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HHV-6-specific T-cell response be assessed by interferon gamma enzyme-linked 
immunosorbent spot assay, and the functional characteristics of HHV-6 specific CD4+ 
and CD8+ T-cells will be determined by intracellular cytokine assays.  
For evaluating humoral response, we propose measuring serum titer of anti-
HHV6 neutralizing antibodies (gB) and anti-U11 antibodies by ELISA. Statistical 
significance of differences in responses between CIHHV-6 and non-CIHHV-6 individuals 
will be assessed using the student’s p-test. 
Functional Characterization of HHV-6 Encoded Proteins 
Considering that HHV-6A and HHV-6B are important human pathogens, there 
have been limited studies characterizing the function of HHV-6 encoded proteins. The 
present study highlighted a number of open reading frames which are either well 
conserved or highly variable from one strain to another. Characterization of genes which 
fall into either of these categories will allow researchers to understand the molecular 
basis for interstrain and intrastrain differences observed for HHV-6 strains.  
Our group previously used an HHV-6A BAC vector to created a chloramphenicol-
selectable green fluorescent-protein (GFP) expressing HHV-6A virus (15); this vector 
allows for manipulation of the viral genome in an E. coli system. First, PCR will be used 
for generating deletion cassettes which contain the flanking region of individual open 
reading frames, the kanamycin gene, and loxP (locus of X-over P1) sites. The purified 
deletion cassette will then be transformed into E.coli cells containing the HHV-6A BAC 
vector and mutants will be selected for by LB agar plates containing chloramphenicol 
and kanamycin. Deletion of selected open reading frames will be confirmed by 
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restriction enzyme digestion and southern blot analysis. To generate revertant mutants 
the recombinant BAC vector can be transformed into E. coli cells expressing the Cre 
(Cyclization recombinase) site-specific recombinase. Recombination will occur, result in 
the deletion of the kanamycin cassette and result in an intact copy of the viral gene.  
After generation of the knockout BAC vector, virus reconstitution will be 
accomplished by transfecting the BAC vector into HEK293 cells and growing the cells 
until cytopathic effect is visible. The recombinant or revertant wild-type virus will then be 
isolated by several freeze thaw cycles and harvesting of supernatant after high speed 
centrifugation to remove cellular debris.  
Once generated, the knockout genes can be assessed for their ability to 
establish latency and be reactivated from latency. Establishment of latency can easily 
be tracked flow cytometry or fluorescent microscopy when working with a GFP 
expressing mutant virus. In our experience cells infected with an HHV-6 GFP 
expressing viruses fluoresce brightly during early times of infection and fluorescence 
intensity lowers as latency is established. Fluorescence should again increase after 
addition of TSA, and induction of viral replication. 
Characterization of Inherited Herpesvirus-6 Genomes 
There is little known about the genetic variability of inherited HHV-6 viruses, and 
future studies should focus on characterizing inherited HHV-6 viruses in detail. 
Restriction fragment analysis and sequencing number of viral genes, suggests that 
inherited HHV-6 viruses are divergent when compared to each other and previously 
characterized HHV-6 viruses. Full genome sequencing of the inherited genome may 
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reveal critical antigen epitope variability in addition to mutations with the potential to 
cause viral replication defects. Sequence variation may also affect the ability of inherited 
viruses to reactivate or determine whether inherited viral genome expression occurs. 
Furthermore, it is also possible that some HHV-6 viruses that have entered the germline 
viruses differ in tropism than other viruses and can more efficiently infect gonad or pre-
gonad cells. These differences may be a contributing factor to why CIHHV-6 is present 
in only a small fraction of the population, although HHV-6 viruses are ubiquitous.   
To characterize inherited HHV-6 sequences, whole genome sequencing can be 
performed on DNA isolated from whole blood of CIHHV-6 positive patients. We propose 
the use of 454 sequencing methodology to accomplish whole genome sequencing of 
the inherited viral genome. We expect that sequencing will be partially incomplete in the 
portions of the viral genome containing repetitive sequences and that PCR amplification 
and cloning will be necessary to complete the viral genome. Assembly of the sequenced 
viral genome will be performed using HHV-6A U1102 or HHV-6B Z29 as reference 
strains. Nucleotide sequences and translated amino acid sequences for individual open 
reading frames will be aligned with prototype sequences, and evaluated for potential 
truncations and significant differences in coding sequences.   
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equal to the number that you identified in the licensing process. Any form of republication 
granted by this license must be completed within two years of the date of the grant of this 
license (although copies prepared before may be distributed thereafter). The Materials shall 
not be used in any other manner or for any other purpose. Permission is granted subject to 
an appropriate acknowledgement given to the author, title of the material/book/journal and 
the publisher. You shall also duplicate the copyright notice that appears in the Wiley 
publication in your use of the Material. Permission is also granted on the understanding 
that nowhere in the text is a previously published source acknowledged for all or part of 
this Material. Any third party material is expressly excluded from this permission. 
3. With respect to the Materials, all rights are reserved. Except as expressly granted by the 
terms of the license, no part of the Materials may be copied, modified, adapted (except for 
minor reformatting required by the new Publication), translated, reproduced, transferred or 
distributed, in any form or by any means, and no derivative works may be made based on 
the Materials without the prior permission of the respective copyright owner. You may not 
alter, remove or suppress in any manner any copyright, trademark or other notices 
displayed by the Materials. You may not license, rent, sell, loan, lease, pledge, offer as 
security, transfer or assign the Materials, or any of the rights granted to you hereunder to 
any other person. 
4. The Materials and all of the intellectual property rights therein shall at all times remain 
the exclusive property of John Wiley & Sons Inc or one of its related companies (WILEY) 
or their respective licensors, and your interest therein is only that of having possession of 
and the right to reproduce the Materials pursuant to Section 2 herein during the continuance 
of this Agreement. You agree that you own no right, title or interest in or to the Materials 
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or any of the intellectual property rights therein. You shall have no rights hereunder other 
than the license as provided for above in Section 2. No right, license or interest to any 
trademark, trade name, service mark or other branding ("Marks") of WILEY or its licensors 
is granted hereunder, and you agree that you shall not assert any such right, license or 
interest with respect thereto. 
5. NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR 
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY, EXPRESS, 
IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS OR THE 
ACCURACY OF ANY INFORMATION CONTAINED IN THE MATERIALS, 
INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY OF 
MERCHANTABILITY, ACCURACY, SATISFACTORY QUALITY, FITNESS FOR A 
PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NON-INFRINGEMENT 
AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED BY WILEY AND ITS 
LICENSORS AND WAIVED BY YOU. 
6. WILEY shall have the right to terminate this Agreement immediately upon breach of 
this Agreement by you. 
7. You shall indemnify, defend and hold harmless WILEY, its Licensors and their 
respective directors, officers, agents and employees, from and against any actual or 
threatened claims, demands, causes of action or proceedings arising from any breach of this 
Agreement by you. 
8. IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR ANY 
OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY SPECIAL, 
CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR PUNITIVE 
DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN CONNECTION WITH 
THE DOWNLOADING, PROVISIONING, VIEWING OR USE OF THE MATERIALS 
REGARDLESS OF THE FORM OF ACTION, WHETHER FOR BREACH OF 
CONTRACT, BREACH OF WARRANTY, TORT, NEGLIGENCE, INFRINGEMENT 
OR OTHERWISE (INCLUDING, WITHOUT LIMITATION, DAMAGES BASED ON 
LOSS OF PROFITS, DATA, FILES, USE, BUSINESS OPPORTUNITY OR CLAIMS OF 
THIRD PARTIES), AND WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF 
THE POSSIBILITY OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY 
NOTWITHSTANDING ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED 
REMEDY PROVIDED HEREIN. 
9. Should any provision of this Agreement be held by a court of competent jurisdiction to 
be illegal, invalid, or unenforceable, that provision shall be deemed amended to achieve as 
nearly as possible the same economic effect as the original provision, and the legality, 
validity and enforceability of the remaining provisions of this Agreement shall not be 
affected or impaired thereby. 
10. The failure of either party to enforce any term or condition of this Agreement shall not 
constitute a waiver of either party's right to enforce each and every term and condition of 
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this Agreement. No breach under this agreement shall be deemed waived or excused by 
either party unless such waiver or consent is in writing signed by the party granting such 
waiver or consent. The waiver by or consent of a party to a breach of any provision of this 
Agreement shall not operate or be construed as a waiver of or consent to any other or 
subsequent breach by such other party. 
11. This Agreement may not be assigned (including by operation of law or otherwise) by 
you without WILEY's prior written consent. 
12. Any fee required for this permission shall be non-refundable after thirty (30) days from 
receipt 
13. These terms and conditions together with CCC's Billing and Payment terms and 
conditions (which are incorporated herein) form the entire agreement between you and 
WILEY concerning this licensing transaction and (in the absence of fraud) supersedes all 
prior agreements and representations of the parties, oral or written. This Agreement may 
not be amended except in writing signed by both parties. This Agreement shall be binding 
upon and inure to the benefit of the parties' successors, legal representatives, and 
authorized assigns. 
14. In the event of any conflict between your obligations established by these terms and 
conditions and those established by CCC's Billing and Payment terms and conditions, these 
terms and conditions shall prevail. 
15. WILEY expressly reserves all rights not specifically granted in the combination of (i) 
the license details provided by you and accepted in the course of this licensing transaction, 
(ii) these terms and conditions and (iii) CCC's Billing and Payment terms and conditions. 
16. This Agreement will be void if the Type of Use, Format, Circulation, or Requestor 
Type was misrepresented during the licensing process. 
17. This Agreement shall be governed by and construed in accordance with the laws of the 
State of New York, USA, without regards to such state's conflict of law rules. Any legal 
action, suit or proceeding arising out of or relating to these Terms and Conditions or the 
breach thereof shall be instituted in a court of competent jurisdiction in New York County 
in the State of New York in the United States of America and each party hereby consents 
and submits to the personal jurisdiction of such court, waives any objection to venue in 
such court and consents to service of process by registered or certified mail, return receipt 
requested, at the last known address of such party. 
Wiley Open Access Terms and Conditions 
Wiley publishes Open Access articles in both its Wiley Open Access Journals program 
[http://www.wileyopenaccess.com/view/index.html] and as Online Open articles in its 
subscription journals. The majority of Wiley Open Access Journals have adopted 
the Creative Commons Attribution License (CC BY) which permits the unrestricted use, 
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distribution, reproduction, adaptation and commercial exploitation of the article in any 
medium. No permission is required to use the article in this way provided that the article is 
properly cited and other license terms are observed. A small number of Wiley Open Access 
journals have retained the Creative Commons Attribution Non Commercial License (CC 
BY-NC), which permits use, distribution and reproduction in any medium, provided the 
original work is properly cited and is not used for commercial purposes. 
Online Open articles - Authors selecting Online Open are, unless particular exceptions 
apply, offered a choice of Creative Commons licenses. They may therefore select from the 
CC BY, the CC BY-NC and the Attribution-NoDerivatives (CC BY-NC-ND). The CC BY-
NC-ND is more restrictive than the CC BY-NC as it does not permit adaptations or 
modifications without rights holder consent. 
Wiley Open Access articles are protected by copyright and are posted to repositories and 
websites in accordance with the terms of the applicable Creative Commons license 
referenced on the article. At the time of deposit, Wiley Open Access articles include all 
changes made during peer review, copyediting, and publishing. Repositories and websites 
that host the article are responsible for incorporating any publisher-supplied amendments 
or retractions issued subsequently. 
Wiley Open Access articles are also available without charge on Wiley's publishing 
platform,Wiley Online Library or any successor sites. 
Conditions applicable to all Wiley Open Access articles: 
• The authors' moral rights must not be compromised. These rights include the right 
of "paternity" (also known as "attribution" - the right for the author to be identified 
as such) and "integrity" (the right for the author not to have the work altered in such 
a way that the author's reputation or integrity may be damaged).  
• Where content in the article is identified as belonging to a third party, it is the 
obligation of the user to ensure that any reuse complies with the copyright policies 
of the owner of that content.  
• If article content is copied, downloaded or otherwise reused for research and other 
purposes as permitted, a link to the appropriate bibliographic citation (authors, 
journal, article title, volume, issue, page numbers, DOI and the link to the definitive 
published version on Wiley Online Library) should be maintained. Copyright 
notices and disclaimers must not be deleted. 
o Creative Commons licenses are copyright licenses and do not confer any 
other rights, including but not limited to trademark or patent rights. 
• Any translations, for which a prior translation agreement with Wiley has not been 
agreed, must prominently display the statement: "This is an unofficial translation of 
an article that appeared in a Wiley publication. The publisher has not endorsed this 
translation."  
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 Conditions applicable to non-commercial licenses (CC BY-NC and CC BY-
NC-ND) 
For non-commercial and non-promotional purposes individual non-commercial 
users may access, download, copy, display and redistribute to colleagues Wiley 
Open Access articles. In addition, articles adopting the CC BY-NC may be adapted, 
translated, and text- and data-mined subject to the conditions above. 
Use by commercial "for-profit" organizations 
Use of non-commercial Wiley Open Access articles for commercial, promotional, 
or marketing purposes requires further explicit permission from Wiley and will be 
subject to a fee. Commercial purposes include: 
o Copying or downloading of articles, or linking to such articles for further 
redistribution, sale or licensing;  
o Copying, downloading or posting by a site or service that incorporates 
advertising with such content;  
o The inclusion or incorporation of article content in other works or services 
(other than normal quotations with an appropriate citation) that is then 
available for sale or licensing, for a fee (for example, a compilation 
produced for marketing purposes, inclusion in a sales pack)  
o Use of article content (other than normal quotations with appropriate 
citation) by for-profit organizations for promotional purposes  
o Linking to article content in e-mails redistributed for promotional, 
marketing or educational purposes;  
o Use for the purposes of monetary reward by means of sale, resale, license, 
loan, transfer or other form of commercial exploitation such as marketing 
products  
o Print reprints of Wiley Open Access articles can be purchased 
from:corporatesales@wiley.com  
The modification or adaptation for any purpose of an article referencing the 
CC BY-NC-ND License requires consent which can be requested 
fromRightsLink@wiley.com . 
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Other Terms and Conditions:  
BY CLICKING ON THE "I AGREE..." BOX, YOU ACKNOWLEDGE 
THAT YOU HAVE READ AND FULLY UNDERSTAND EACH OF THE 
SECTIONS OF AND PROVISIONS SET FORTH IN THIS AGREEMENT 
AND THAT YOU ARE IN AGREEMENT WITH AND ARE WILLING 
TO ACCEPT ALL OF YOUR OBLIGATIONS AS SET FORTH IN THIS 
AGREEMENT. 
 
v1.8 
If you would like to pay for this license now, please remit this license along with your 
payment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise you will be 
invoiced within 48 hours of the license date. Payment should be in the form of a check 
or money order referencing your account number and this invoice number 
RLNK501146743. 
Once you receive your invoice for this order, you may pay your invoice by credit card. 
Please follow instructions provided at that time. 
 
Make Payment To: 
Copyright Clearance Center 
Dept 001 
P.O. Box 843006 
Boston, MA 02284-3006 
 
For suggestions or comments regarding this order, contact RightsLink Customer 
Support:customercare@copyright.com or +1-877-622-5543 (toll free in the US) or +1-
978-646-2777. 
Gratis licenses (referencing $0 in the Total field) are free. Please retain this printable 
license for your reference. No payment is required. 
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APPENDIX 2 (continued) 
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APPENDIX 2 (continued) 
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APPENDIX 2 (continued) 
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